Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang
Clin Mol Hepatol 2025;31(3):810-822. Published online January 17, 2025
Background/Aims Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.
Methods In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.
Results The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF use before enrollment was 4.14 years. After 48 weeks, 100.0% and 98.5% patients in the BSV and TDF groups, respectively, met the primary endpoint (HBV DNA <20 IU/mL), demonstrating the non-inferior antiviral efficacy of BSV to TDF (95% confidence interval –0.01 to 0.04; P>0.999), with a predefined margin of –0.18. The mean percentage changes in estimated glomerular filtration rates were slightly better in the BSV group (1.67±11.73%) than in the TDF group (–1.24±11.02%). The BSV group showed a significant improvement in bone turnover biomarkers compared to the TDF group; accordingly, hip and spine bone mineral density increased in the BSV group.
Conclusions In patients with CHB receiving long-term TDF, switching to BSV may improve renal and bone safety with non-inferior antiviral efficacy compared to that of maintaining TDF.
Citations
Citations to this article as recorded by
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu World Journal of Gastroenterology.2025;[Epub] CrossRef
Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial” Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Jihyun An, Young Eun Chon, Gunho Kim, Mi Na Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Miyoung Choi, Dae Won Jun, Seung Up Kim, Ji Won Han, Young-Joo Jin
Clin Mol Hepatol 2024;30(Suppl):S134-S146. Published online August 21, 2024
Background/Aims The assessment of liver fibrosis is crucial for managing autoimmune liver diseases such as primary biliary cholangitis (PBC), autoimmune hepatitis (AIH), and primary sclerosing cholangitis (PSC). However, data on the efficacy of noninvasive tests for these diseases are limited. This meta-analysis evaluated the diagnostic accuracy of vibration-controlled transient elastography (VCTE) for staging fibrosis in patients with autoimmune liver disease.
Methods Searches were conducted in PubMed, Embase, CINAHL, Web of Science, and Cochrane Library databases to assess the diagnostic accuracy of VCTE against histology as the reference standard in adult patients with autoimmune liver disease. The summary area under the curve (sAUC) and diagnostic odds ratio were calculated for significant fibrosis (SF), advanced fibrosis (AF), and cirrhosis, according to liver biopsy.
Results Fourteen articles were included, comprising 559 PBC patients from six studies, 388 AIH patients from five studies, and 151 PSC patients from three studies. VCTE demonstrated good performance for fibrosis staging in PBC, AIH, and PSC. In PBC, sAUCs of VCTE were 0.87, 0.89, and 0.99 for staging SF, AF, and cirrhosis, respectively. In AIH, the sAUCs were 0.88, 0.88, and 0.92, respectively, while in PSC, they were 0.88, 0.95, and 0.92, respectively. The cutoff values for AF were 7.5–17.9 kPa in PBC, 8.18–12.1 kPa in AIH, and 9.6 kPa in PSC.
Conclusions VCTE shows high diagnostic accuracy for staging liver fibrosis in patients with autoimmune liver diseases. This non-invasive method serves as a valuable tool for the evaluation and monitoring of fibrosis in these lifelong diseases.
Citations
Citations to this article as recorded by
Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on “Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver di Kyung-Ah Kim Clinical and Molecular Hepatology.2025; 31(1): 275. CrossRef
Diagnostic value of serum Golgi protein 73 in liver fibrosis and inflammation in patients with autoimmune hepatitis Yazhen Zhang, Aifang Xu, Yujiao Jin, Jing Gao, Jiahui He Medicine.2025; 104(26): e43064. CrossRef
Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen Pharmacological Research.2025; 217: 107823. CrossRef
Diagnostic Performance of SWE and Predictive Models Based on SWE for Post-Hepatectomy Liver Failure: A Systematic Review and Meta-analysis Jiaxu Liang, Fukun Shi, Lan Zhang, Suo Yin, Yong Chen Current Medical Imaging Formerly Current Medical Imaging Reviews.2025;[Epub] CrossRef
Hidden weaknesses and biological insights in machine learning models of fibrosis in autoimmune hepatitis Shiuan-Chih Chen, Chun-Chieh Chen QJM: An International Journal of Medicine.2025;[Epub] CrossRef
Background/aims Opinions differ regarding vibration-controlled transient elastography and magnetic resonance elastography (VCTE/MRE) cut-offs for diagnosing advanced fibrosis (AF) in patients with non-alcoholic fatty liver disease (NAFLD). We investigated the diagnostic performance and optimal cut-off values of VCTE and MRE for diagnosing AF.
Methods Literature databases, including Medline, EMBASE, Cochrane Library, and KoreaMed, were used to identify relevant studies published up to June 13, 2023. We selected studies evaluating VCTE and MRE regarding the degree of liver fibrosis using liver biopsy as the reference. The sensitivity, specificity, and area under receiver operating characteristics curves (AUCs) of the pooled data for VCTE and MRE for each fibrosis stage and optimal cut-offs for AF were investigated.
Results A total of 19,199 patients from 63 studies using VCTE showed diagnostic AUC of 0.83 (95% confidence interval: 0.80–0.86), 0.83 (0.80–0.86), 0.87 (0.84–0.90), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. Similarly, 1,484 patients from 14 studies using MRE showed diagnostic AUC of 0.89 (0.86–0.92), 0.92 (0.89–0.94), 0.89 (0.86–0.92), and 0.94 (0.91–0.96) for ≥F1, ≥F2, ≥F3, and F4 stages, respectively. The diagnostic AUC for AF using VCTE was highest at 0.90 with a cut-off of 7.1–7.9 kPa, and that of MRE was highest at 0.94 with a cut-off of 3.62–3.8 kPa.
Conclusions VCTE (7.1–7.9 kPa) and MRE (3.62–3.8 kPa) with the suggested cut-offs showed favorable accuracy for diagnosing AF in patients with NAFLD. This result will serve as a basis for clinical guidelines for non-invasive tests and differential diagnosis of AF.
Citations
Citations to this article as recorded by
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analy Young Eun Chon, Jung Hwan Yu, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(1): e61. CrossRef
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib Won Sohn Clinical and Molecular Hepatology.2025; 31(1): 277. CrossRef
Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analys Jung Hwan Yu, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(1): e52. CrossRef
Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver d Yangyue Zhang, Vincent Wai-Sun Wong Clinical and Molecular Hepatology.2025; 31(1): 264. CrossRef
Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study Laura De Rosa, Gabriele Ricco, Maurizia Rossana Brunetto, Ferruccio Bonino, Francesco Faita Healthcare.2025; 13(7): 759. CrossRef
Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study Dan-Ionuț Gheonea, Cristina Tocia, Victor-Mihai Sacerdoțianu, Alexandra-Georgiana Bocioagă, Irina-Paula Doica, Nicolae Cătălin Manea, Adina Turcu-Știolică, Carmen-Nicoleta Oancea, Eugen Dumitru International Journal of Molecular Sciences.2025; 26(12): 5427. CrossRef
Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study Xue Lu, Haoyan Zhang, Hidekatsu Kuroda, Matteo Garcovich, Victor de Ledinghen, Ivica Grgurević, Runze Linghu, Hong Ding, Jiandong Chang, Min Wu, Cheng Feng, Xinping Ren, Changzhu Liu, Tao Song, Fankun Meng, Yao Zhang, Ye Fang, Sumei Ma, Jinfen Wang, Xiaol Visual Computing for Industry, Biomedicine, and Art.2025;[Epub] CrossRef
Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography Ernesto Maddaloni, Marta Zerunian, Vincenzo Cardinale, Annalisa Zurru, Rocco Amendolara, Daniela Luverà, Renata Risi, Luca D’Onofrio, Benedetta Masci, Francesco Covotta, Damiano Caruso, Domenico Alvaro, Andrea Laghi, Raffaella Buzzetti Diabetes Research and Clinical Practice.2025; 229: 112465. CrossRef
Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang Hepatology Communications.2025;[Epub] CrossRef
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei Cell Biochemistry and Function.2025;[Epub] CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef
Jung Hwan Yu, Ji Won Han, Young Ju Suh, Young Eun Chon, Hee Yeon Kim, Ji Hyun An, Young-Joo Jin, Miyoung Choi, Seung Up Kim, Dae Won Jun, Han Ah Lee, Mi Na Kim
Clin Mol Hepatol 2024;30(Suppl):S186-S198. Published online August 21, 2024
Backgrounds/Aims This meta-analysis examined whether preoperative vibration-controlled transient elastography (VCTE) can predict postoperative complications and recurrence in patients undergoing hepatic resection for hepatocellular carcinoma (HCC).
Methods A systematic literature search was conducted using Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases. Out of 431 individual studies, thirteen published between 2008 and 2022 were included. Five studies focused on HCC recurrence, while eight examined postoperative complications.
Results The meta-analysis of five studies on HCC recurrence showed that the high-risk group with a high VCTE score had a significantly increased recurrence rate after hepatic resection (hazard ratio 2.14). The cutoff value of VCTE in the high-risk group of HCC recurrence was 7.4–13.4 kPa, the sensitivity was 0.60 (95% confidence interval [CI] 0.47–0.72), and the specificity was 0.60 (95% CI 0.46–0.72). The area under the receiver operating characteristic curve (AUC) of the liver stiffness measured by VCTE to predict the HCC recurrence was 0.63 (95% CI 0.59–0.67). The meta-analysis on the postoperative complications revealed a significantly increased risk of postoperative complications in the high-risk group (12–25.6 kPa) with a high VCTE value (odds ratio [OR], 8.32). The AUC of the liver stiffness measured by VCTE to predict the postoperative complications was 0.87 (95% CI 0.84–0.90), the sensitivity was 0.76 (95% CI 0.55–0.89) and the specificity was 0.85 (95% CI 0.73–0.92).
Conclusions This meta-analysis suggests that preoperative VCTE in patients undergoing hepatic resection for HCC is useful in identifying individuals at a high risk of postoperative complications and HCC recurrence.
Citations
Citations to this article as recorded by
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2024;30(Suppl):S5-S105. Published online August 19, 2024
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef
Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography Ji Won Han The Korean Journal of Medicine.2025; 100(1): 26. CrossRef
Influence of Sex in the Development of Liver Diseases Jie-Wen Zhang, Nan Zhang, Yi Lyu, Xu-Feng Zhang Seminars in Liver Disease.2025; 45(01): 015. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study G. Craig Wood, Anthony Hoovler, Rakesh Luthra, Christopher D. Still, Hamzah Shariff, Matthew Still, Jonathan Hayes, Peter Benotti, Chioma Uzoigwe Expert Review of Gastroenterology & Hepatology.2025; 19(4): 427. CrossRef
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv Ji Won Han, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(2): e152. CrossRef
The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang BMC Gastroenterology.2025;[Epub] CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C Beom Kyung Kim Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients Guanlan Liu, Li Liu, Xing Yang, Qihao Wang, Mingqin Qian Journal of Clinical and Experimental Hepatology.2025; 15(6): 102610. CrossRef
A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee The Journal of Internal Korean Medicine.2025; 46(2): 303. CrossRef
Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Clinical and Molecular Hepatology.2025; 31(3): 1018. CrossRef
Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population Jean-Bonny Nsumbu, Jean-Robert Makulo, Trésor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi Hepatic Medicine: Evidence and Research.2025; Volume 17: 27. CrossRef
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2025;[Epub] CrossRef
Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag Scientific Reports.2025;[Epub] CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim Medicina.2025; 61(9): 1601. CrossRef
Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz Clinical and Molecular Hepatology.2025; 31(4): 1167. CrossRef
Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li European Journal of Medical Research.2025;[Epub] CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef
Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography Mi Na Kim The Korean Journal of Gastroenterology.2024; 84(5): 201. CrossRef
Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B Ye Ji Jun, Minjong Lee, Ho Soo Chun, Tae Hun Kim The Korean Journal of Gastroenterology.2024; 84(5): 206. CrossRef
Serological Markers to Assess Liver Fibrosis and Their Roles Beom Kyung Kim The Korean Journal of Gastroenterology.2024; 84(5): 195. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Backgrounds/Aims Despite advances in antiviral therapy for hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC) still develops even after sustained viral response (SVR) in patients with advanced liver fibrosis or cirrhosis. This meta-analysis investigated the predictive performance of vibration-controlled transient elastography (VCTE) and fibrosis 4-index (FIB-4) for the development of HCC after SVR.
Methods We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for studies examining the predictive performance of these tests in adult patients with HCV. Two authors independently screened the studies’ methodological quality and extracted data. Pooled estimates of sensitivity, specificity, and area under the curve (AUC) were calculated for HCC development using random-effects bivariate logit normal and linear-mixed effect models.
Results We included 27 studies (169,911 patients). Meta-analysis of HCC after SVR was possible in nine VCTE and 15 FIB-4 studies. Regarding the prediction of HCC development after SVR, the pooled AUCs of pre-treatment VCTE >9.2–13 kPa and FIB-4 >3.25 were 0.79 and 0.73, respectively. VCTE >8.4–11 kPa and FIB-4 >3.25 measured after SVR maintained good predictive performance, albeit slightly reduced (pooled AUCs: 0.77 and 0.70, respectively). The identified optimal cut-off value for HCC development after SVR was 12.6 kPa for pre-treatment VCTE. That of VCTE measured after the SVR was 11.2 kPa.
Conclusions VCTE and FIB-4 showed acceptable predictive performance for HCC development in patients with HCV who achieved SVR, underscoring their utility in clinical practice for guiding surveillance strategies. Future studies are needed to validate these findings prospectively and validate their clinical impact.
Citations
Citations to this article as recorded by
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus Xinpu Miao, Haidong Wu, Jinrong Xu, Wei Cheng Clinical and Molecular Hepatology.2025; 31(1): e23. CrossRef
Hepatocellular carcinoma surveillance after sustained virological response in chronic hepatitis C: Editorial on “Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-ana Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2025; 31(1): 261. CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim Medicina.2025; 61(9): 1601. CrossRef
Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines Masaaki Mino, Eiji Kakazu, Tatsuya Kanto Gut and Liver.2025; 19(5): 651. CrossRef
Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C Yu Rim Lee, Hyun Young Woo, Young Oh. Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang, Woo Jin Chung, Jeong Heo, Nae‐Yun Heo, Seung Ha Park, Jun Sik Yoon, J Journal of Gastroenterology and Hepatology.2025; 40(10): 2568. CrossRef
Diagnostic possibilities of perfusion computed tomography in assessing fibrosis regression in patients with chronic viral hepatitis C: a prospective study E. A. Ioppa, O. S. Tonkikh, I. Yu. Degtyarev, V. D. Zavadovskaya, E. S. Garganeeva Diagnostic radiology and radiotherapy.2025; 16(3): 65. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Background/Aims Although important, clinically significant liver fibrosis is often overlooked in the general population. We aimed to examine the prevalence of clinically significant liver fibrosis using noninvasive tests (NITs) in the general population.
Methods We collected data from four databases (MEDLINE, Embase, Cochrane Library, and KoreaMed) from inception to June 13, 2023. Original articles reporting the prevalence of clinically significant liver fibrosis in the general population were included. The Stata metaprop function was used to obtain the pooled prevalence of liver fibrosis with NITs in the general population.
Results We screened 6,429 articles and included 45 eligible studies that reported the prevalence of clinically significant liver fibrosis in the general population. The prevalence of advanced liver fibrosis, using the high probability cutoff of the fibrosis-4 (FIB-4) index, was 2.3% (95% confidence interval [CI], 1.2–3.7%). The prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, assessed using vibration-controlled transient elastography (VCTE) among the general population, was 7.3% (95% CI, 5.9–8.8%), 3.5% (95% CI, 2.7–4.5), and 1.2% (95% CI, 0.8–1.8%), respectively. Region-based subgroup analysis revealed that the highest prevalence of advanced fibrosis using the high probability cutoff of the FIB-4 index was observed in the American region. Furthermore, the American region exhibited the highest prevalence of significant liver fibrosis, advanced liver fibrosis, and liver cirrhosis, using VCTE.
Conclusions Previously undiagnosed clinically significant liver fibrosis is found in the general population through NITs. Future research is necessary to stratify the risk in the general population.
Citations
Citations to this article as recorded by
Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Nana Peng, Mary Yue Wang, Sherlot Juan Song, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(1): 256. CrossRef
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e48. CrossRef
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population” Wei Feng, Qile Wang, Qingwang Ye Clinical and Molecular Hepatology.2025; 31(1): e21. CrossRef
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis” Hee Yeon Kim, Miyoung Choi, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e105. CrossRef
Hypoxia-inducible factor-1 alpha (HIF-1α) inhibitor AMSP-30 m attenuates CCl4-induced liver fibrosis in mice by inhibiting the sonic hedgehog pathway Lili Lu, Yuchen Ma, Qing Tao, Jing Xie, Xiao Liu, Yongkang Wu, Yang Zhang, Xiuli Xie, Mingming Liu, Yong Jin Chemico-Biological Interactions.2025; 413: 111480. CrossRef
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng Clinical and Molecular Hepatology.2025; 31(2): 620. CrossRef
Simple Clinical Prediction Rules for Identifying Significant Liver Fibrosis: Evaluation of Established Scores and Development of the Aspartate Aminotransferase-Thrombocytopenia-Albumin (ATA) Score Puwitch Charoenchue, Jiraporn Khorana, Apichat Tantraworasin, Suwalee Pojchamarnwiputh, Wittanee Na Chiangmai, Amonlaya Amantakul, Taned Chitapanarux, Nakarin Inmutto Diagnostics.2025; 15(9): 1119. CrossRef
Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen Pharmacological Research.2025; 217: 107823. CrossRef
Decoding the hepatic fibrosis-hepatocellular carcinoma axis: from mechanisms to therapeutic opportunities Anqi Lin, Minying Xiong, Bufu Tang, Aimin Jiang, Junyi Shen, Zaoqu Liu, Quan Cheng, Jian Zhang, Peng Luo Hepatology International.2025; 19(4): 732. CrossRef
Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests Huiyul Park, Eileen L. Yoon, Mimi Kim, Ji-hyeon Park, Ramsey Cheung, Jeong-Yeon Cho, Hye-Lin Kim, Dae Won Jun Scientific Reports.2025;[Epub] CrossRef
Senkyunolide I targets CXCR4 to attenuate liver fibrosis via suppression of the NLRP3/GSDMD pathway Kexin Wang, Yuxin Yang, Bingjie Yue, Mengyang Li, Chu Chen, Junrong Du, Fangyi Long International Immunopharmacology.2025; 164: 115348. CrossRef
Chronic liver disease and radiation-induced second primary liver malignancy: a retrospective cohort based on SEER database 2010–2021 Asmaa Ellaithy, Aya Serageldeen, Alhareth Alhusban, Mariam Emad Seif, Mahmoud Essam Abdelhamid, Bushra Al-Shaikh, Asmaa Sayed Ibrahim, Eslam Mohamed Elshennawy, Ibrahim Ellaithy Annals of Medicine & Surgery.2025; 87(8): 4742. CrossRef
PREVALENCE OF VARIOUS ETIOPATHOGENIC VARIANTS OF CHRONIC DIFFUSE LIVER DISEASES B. Sakhova, A. Oshibayeva, N. Nuskabayeva, E. Iskandirova, Zh. Rsalieva, N. Karabayev, L. Karimova, L. Ozbakyr Medicine and ecology.2025; (3): 35. CrossRef
Association between gestational diabetes mellitus and liver cirrhosis and fibrosis: A population‐based cohort study and risk factor analysis Tan‐Tzu Lo, Wan‐Ting Huang, Chia‐Lung Shih, Pensee Wu International Journal of Gynecology & Obstetrics.2025;[Epub] CrossRef
Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis Jonghyun Kim, Takanori Ito, Taeang Arai, Masanori Atsukawa, Miwa Kawanaka, Hidenori Toyoda, Takashi Honda, Ming-Lung Yu, Eileen L. Yoon, Dae Won Jun, Kyungjoon Cha, Mindie H. Nguyen Diagnostics.2024; 14(22): 2500. CrossRef
Background/Aims The Fibrosis-4 index (FIB-4) is a noninvasive test widely used to rule out advanced liver fibrosis (AF) in patients with nonalcoholic fatty liver disease (NAFLD). However, its diagnostic accuracy in NAFLD patients with type 2 diabetes mellitus (T2DM) is controversial due to the high prevalence of AF in this population.
Methods Research focusing on the diagnostic accuracy of FIB-4 for liver fibrosis as validated by liver histology in NAFLD patients with T2DM was included, and 12 studies (n=5,624) were finally included in the meta-analysis. Sensitivity, specificity, hierarchical summary receiver operating characteristic (HSROC), positive predictive values (PPVs), and negative predictive values (NPVs) at low cutoffs (1.3–1.67) and high cutoffs (2.67–3.25) for ruling in and out AF were calculated.
Results At low cutoffs, the meta-analysis revealed a sensitivity of 0.74, specificity of 0.62, and HSROC of 0.75. At high cutoffs, the analysis showed a sensitivity of 0.33, specificity of 0.92, and HSROC of 0.85, suggesting FIB-4 as useful for identifying or excluding AF. In subgroup analyses, high mean age and F3 prevalence were associated with lower sensitivity. The calculated NPV and PPV were 0.82 and 0.49 at low cutoffs, whereas the NPV was 0.28 and the PPV was 0.70 at high cutoffs. There were insufficient estimated NPVs <0.90 at a hypothesized prevalence of AF >30% at an FIB-4 cutoff range of 1.3–1.67.
Conclusions Collectively, FIB-4 has moderate diagnostic accuracy for identifying or excluding AF in NAFLD patients with T2DM, but more evidence must be accumulated due to the limited number of currently reported studies and their heterogeneity.
Citations
Citations to this article as recorded by
Prognostic value of the FIB-4 index in patients with myocardial infarction with non-obstructive coronary arteries Wei Zhang, Yuqi Chen, Liu Zhu, Siliang Peng, Mengchao Jin, Jiayu Yin International Journal of Cardiology.2026; 445: 134045. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?” Moon Haeng Hur, Jeong-Hoon Lee Journal of Hepatology.2025; 82(3): e143. CrossRef
The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang Clinical and Molecular Hepatology.2025; 31(1): e25. CrossRef
Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography Ji Won Han The Korean Journal of Medicine.2025; 100(1): 26. CrossRef
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv Ji Won Han, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(2): e152. CrossRef
Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen Pharmacological Research.2025; 217: 107823. CrossRef
Comparison of FIB-4, APRI and AST/ALT ratio with FibroScan in patients with NAFLD and type 2 diabetes: a single-center study from Bangladesh Muhammad Shah Alam, Syeda Tanzina Kalam, Monirul Islam Khan, Jabed Ahmed, Rahul Saha, A. B. M. Kamrul-Hasan Egyptian Liver Journal.2025;[Epub] CrossRef
Part 2: CAR Metabolic Dysfunction-Associated Steatotic Liver Disease Working Group Recommendations for Risk Stratifying Patients With MASLD Mitchell P. Wilson, Gavin Low, Abdel-Aziz Shaheen, Andreu F. Costa, An Tang, Emily Pang, Silvia Chang, Alexandra Medellin, Jérémy Dana, Noam Millo, Ania Kielar, Li Xin Zhang, Toni Whitaker, Mark Swain, Victoria Leung, Daisy Fung, Casey Hurrell, Christophe Canadian Association of Radiologists Journal.2025;[Epub] CrossRef
Impact of a high dietary fiber cereal meal intervention on the progression of liver fibrosis in T2DM with MASLD Xi-Shuang Chen, Hui-Zhen Liu, Fang Huang, Jian Meng, Jing-Xian Fang, Yu Han, Hui-Ming Zou, Qing Gu, Xue Hu, Qian-Wen Ma, Yue-Xia Han, Sui-Jun Wang Frontiers in Endocrinology.2025;[Epub] CrossRef
Association between fibrosis-4 index and coronary heart disease: a population-based study Pan Jia, Mamajan Annamyradova, Genhao Fan, Qizhen Zhang, Yankun Song, Qiaozhi Li, Minghao Liu, Zuoying Xing, Yongxia Wang BMC Cardiovascular Disorders.2025;[Epub] CrossRef
Forns index and fatty liver index, but not FIB-4, are associated with indices of glycaemia, pre-diabetes and type 2 diabetes: analysis of The Maastricht Study Leen Heyens, Hanna Kenjic, Pieter Dagnelie, Casper Schalkwijk, Coen Stehouwer, Steven Meex, Jeroen Kooman, Otto Bekers, Marleen van Greevenbroek, Hans Savelberg, Geert Robaeys, Bastiaan de Galan, Annemarie Koster, Martien van Dongen, Simone Eussen, Ger Ko BMJ Open Gastroenterology.2024; 11(1): e001466. CrossRef
Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi
Clin Mol Hepatol 2024;30(Suppl):S106-S116. Published online July 23, 2024
Backgrounds/Aims Accurate diagnosis of significant liver fibrosis in patients with chronic hepatitis B (CHB) is crucial when determining whether to initiate antiviral treatment (AVT). We conduct a meta-analysis to assess the diagnostic performance of vibration-controlled transient elastography (VCTE) for significant liver fibrosis in AVT-naïve CHB patients with serum alanine transaminase (ALT) levels within 5-fold the upper limit of normal (ULN).
Methods The Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases were searched to identify studies that compared the performance of VCTE and liver biopsy (reference standard) when diagnosing significant liver fibrosis (≥F2) in AVT-naïve CHB patients with ALT within 5-fold the ULN. A hierarchical summary receiver operating characteristic curve (HSROC) and bivariate model were performed to evaluate the diagnostic performance of VCTE in the meta-analysis.
Results Eight studies (2,003 patients) were included. The summary sensitivity and specificity for diagnosis of significant liver fibrosis were 0.78 (95% confidence interval [CI], 0.66–0.86) and 0.72 (95% CI, 0.60–0.82), respectively. The HSROC for the diagnosis of significant liver fibrosis was 0.81 (95% CI, 0.72–0.86). The optimal cutoff value of VCTE for diagnosis of significant liver fibrosis was 7.7 kPa with a sensitivity of 0.64 (95% CI, 0.50–0.76) and specificity of 0.83 (95% CI, 0.72–0.90).
Conclusions Our study demonstrated that VCTE has an acceptable diagnostic performance for significant liver fibrosis in AVT-naïve CHB patients with ALT within 5-fold the ULN.
Citations
Citations to this article as recorded by
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K Journal of Gastroenterology and Hepatology.2025; 40(6): 1595. CrossRef
Assessing Liver Fibrosis in Chronic Hepatitis B: Liver Biopsy or Non-Invasive Fibrosis Markers? Deniz Borcak, Zuhal Yesilbag, Yusuf Emre Ozdemir, Adile Sevde Demir, Esra Salim Dogdas, Aysegul Inci Sezen, Esra Canbolat Unlu, Sevtap Senoglu, Hayat Kumbasar Karaosmanoglu, Kadriye Kart Yasar Journal of Clinical Medicine.2025; 14(22): 8164. CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography Mi Na Kim The Korean Journal of Gastroenterology.2024; 84(5): 201. CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Young-Joo Jin, Hee Yeon Kim, Young Ju Suh, Chae Hyeon Lee, Jung Hwan Yu, Mi Na Kim, Ji Won Han, Han Ah Lee, Jihyun An, Young Eun Chon, Dae Won Jun, Miyoung Choi, Seung Up Kim
Clin Mol Hepatol 2024;30(Suppl):S159-S171. Published online July 23, 2024
Backgrounds/Aims Liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE) can assess fibrotic burden in chronic liver diseases. The systematic review and meta-analysis was conducted to determine whether LSM using VCTE can predict the risk of development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients.
Methods A systematic literature search of the Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases (from January 2010 to June 2023) was conducted. Of the 1,345 individual studies identified, 10 studies that used VCTE were finally registered. Hazard ratios (HRs) and the 95% confidence intervals (CIs) were considered summary estimates of treatment effect sizes of ≥11 kilopascal (kPa) standard for HCC development. Meta-analysis was performed using the restricted Maximum Likelihood random effects model.
Results Among the ten studies, data for risk ratios for HCC development could be obtained from nine studies. When analyzed for the nine studies, the HR for HCC development was high at 3.33 (95% CI, 2.45–4.54) in CHB patients with a baseline LSM of ≥11 kPa compared to patients who did not. In ten studies included, LSM of ≥11 kPa showed the sensitivity and specificity for predicting HCC development were 61% (95% CI, 50–71%) and 78% (95% CI, 66–86%), respectively, and the diagnostic accuracy was 0.74 (95% CI, 0.70–0.77).
Conclusions The risk of HCC development was elevated in CHB patients with VCTE-determined LSM of ≥11 kPa. This finding suggests that VCTE-determined LSM values may aid the risk prediction of HCC development in CHB patients.
Citations
Citations to this article as recorded by
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: S Mirko Zoncapè, Emmanuel A. Tsochatzis Clinical and Molecular Hepatology.2025; 31(1): 268. CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B Jiwon Yang, Mark D. Muthiah, Won-Mook Choi Current Hepatology Reports.2025;[Epub] CrossRef
Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis Nobuharu Tamaki, Daniel Q. Huang, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim, Hironori Ochi, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Masayuki Kurosaki, Beom Kyung K Journal of Gastroenterology and Hepatology.2025; 40(6): 1595. CrossRef
Discovering the metabolic pathway of liver disease by breath mass spectrometry combined with machine learning Xuanzhu Li, Wenbo Zhang, Tongtong Yang, Ying Zhang, Rui Su Journal of Pharmaceutical and Biomedical Analysis.2025; 265: 116988. CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C Beom Kyung Kim Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis” Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2025;[Epub] CrossRef
EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection Shichuan Tang, Tingfeng Huang, Ruijing Tang, Kongying Lin, Cong Luo, Yubing Shen, Kailing Zhang, Yidan Tang, Jie Kong, Zhenwei Chen, Jun Fu, Qizhu Lin, Luobin Guo, Yeye Wu, Yuntong Li, Jianxi Zhang, Zhenghong Sun, Penghui You, Daichang Zhang, Yanxin Chen, Gut.2025; : gutjnl-2025-335449. CrossRef
The Evolving Application of Ultrasound in the Precision Management of Small Hepatocellular Carcinoma Xin Guan, Xinyuan Hu, Hong Han, Dezhi Zhang, Huixiong Xu Advanced Ultrasound in Diagnosis and Therapy.2025; 9(4): 375. CrossRef
Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim, Research Committee of the Korean Liver Cancer Association
Clin Mol Hepatol 2023;29(3):521-541. Published online July 1, 2023
Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.
Citations
Citations to this article as recorded by
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer Yuqi Feng, Letian Fang, Guangwen Cao Hepatoma Research.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis” Moon Haeng Hur, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(1): e93. CrossRef
A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges Shuwei Zhou, Chenxin Song, Pei Liu, Shenghong Ju, Yuan-Cheng Wang European Journal of Radiology.2025; 186: 112057. CrossRef
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM Jiahao Li, Lei Xian, Xinsen Wang, Yingnan Liu, Jiarui Li Frontiers in Immunology.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study Yi Zhang, Ze Zhang, Xiaoxv Yin, Anhui Xu, Yonghong Hao, Nan Jiang, Ruibing Zhou, Ketao Mu European Radiology.2025; 35(10): 6564. CrossRef
A risk prediction model for nausea and vomiting after TACE: a cross-sectional study Yali Dai, Mengting Zeng, Hong He, Miao Cai BMC Gastroenterology.2025;[Epub] CrossRef
Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound Linda Galasso, Jacopo Iaccarino, Giorgio Esposto, Gabriele Giansanti, Irene Mignini, Raffaele Borriello, Gianpaolo Vidili, Antonio Gasbarrini, Maria Elena Ainora, Maria Assunta Zocco Diagnostics.2025; 15(11): 1380. CrossRef
Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective In Joon Lee, Hyo-Cheol Kim Korean Journal of Radiology.2025; 26(7): 688. CrossRef
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Ramanpreet Singh, Mina S. Makary Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim Journal of Hepatocellular Carcinoma.2025; Volume 12: 1991. CrossRef
Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial Yanting Zou, Szu‐Yuan Wu, Wanqin Zhang, Wei Zhang, Xizhong Shen, Xudong Qu, Qunyan Yao Liver International.2025;[Epub] CrossRef
Embolic efficacy and safety profile of UniPearls® microspheres for hepatic artery embolization in domestic pigs Junqing Xi, Kai Liu, Min Xu, Li Dai, Zhengqiang Yang, Baosheng Ren Journal of Materials Science: Materials in Medicine.2025;[Epub] CrossRef
Nomogram for predicting post-transarterial chemoembolization survival in recurrent patients with hepatitis B virus-associated hepatocellular carcinoma Zhang-you Guo, Mu-yang Tu, Yin-shan Yang, Ling-xiang Xu, Dan-dan Fan Scientific Reports.2025;[Epub] CrossRef
Reassessing the L. reuteri/ indole-3-lactic acid pathway in TACE-related liver injury Xiang Zhang, Hui gong, Datian Chen Journal of Hepatology.2025;[Epub] CrossRef
Targeting lactic acidosis in the tumor microenvironment: Enhancing tace efficacy in hepatocellular carcinoma Shuyi Hao, Hong Yao, Haojie Yu, Lijun Wang, Tingdong Yu, Hongping Xia, Yong Zha Liver Research.2025;[Epub] CrossRef
Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure Jiahao Li, Yingnan Liu, Ruipeng Zheng, Chao Qu, Jiarui Li Life Sciences.2024; 342: 122540. CrossRef
Rhein‐based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization Xiaoliu Liang, Hui Liu, Hu Chen, Xuqi Peng, Zhenjie Li, Minglei Teng, Yisheng Peng, Jiwei Li, Linyu Ding, Jingsong Mao, Chengchao Chu, Hongwei Cheng, Gang Liu Aggregate.2024;[Epub] CrossRef
Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim Journal of Gastroenterology and Hepatology.2024; 39(9): 1924. CrossRef
Modular multimodal hospital-home chain physical activity rehabilitation programme (3M2H-PARP) in liver cancer: a protocol for a randomised controlled trial Haiyan Chen, Hanxiao Lu, Huimin Zhou, Bo Wu, Zhixia Dong, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang BMJ Open.2024; 14(5): e083228. CrossRef
Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022 Yuri Cho, Bo Hyun Kim, Young-Suk Lim Digestive Disease Interventions.2024; 08(03): 169. CrossRef
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis Huipeng Fang, Qiao Ke, Shiji Wu, Qiang Tu, Lei Wang Frontiers in Immunology.2024;[Epub] CrossRef
Dexamethasone and N-acetylcysteine before transarterial chemoembolization in hepatocellular carcinoma: A Western perspective Marco Biolato, Maurizio Pompili World Journal of Gastroenterology.2024; 30(31): 3635. CrossRef
Research progress on machine algorithm prediction of liver cancer prognosis after intervention therapy Feng Guo American Journal of Cancer Research.2024; 14(9): 4580. CrossRef
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma? Hyo-Cheol Kim Clinical and Molecular Hepatology.2023; 29(4): 984. CrossRef
Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion Dan Yang, Jiaojiao Du, Weijie Nie, Chaozhi Wang, Zhufang Ma Medicine.2023; 102(45): e35713. CrossRef
Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim
Clin Mol Hepatol 2023;29(3):763-778. Published online May 30, 2023
Background/Aims Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine kinase inhibitor (TKI) in patients with HCC and PVTT remains unclear. We compared the outcomes of TARE and TKI therapy in treatment-naïve patients with locally advanced HCC and segmental or lobar PVTT.
Methods This multicenter study included 216 patients initially treated with TARE (n=124) or TKI (sorafenib or lenvatinib; n=92) between 2011 and 2021. Baseline characteristics were balanced using propensity score matching (PSM) or inverse probability of treatment weighting (IPTW). The primary outcome was overall survival (OS). The secondary outcomes included progression-free survival (PFS) and objective response rate (ORR).
Results In the unmatched cohort, the median OS of the TARE and TKI groups were 28.2 and 7.2 months, respectively (p<0.001), and the TARE group experienced significantly and independently longer OS compared to the TKI group (adjusted hazard ratio=0.41, 95% confidence interval=0.28–0.60, p<0.001). Similar results were observed in the study cohorts balanced with IPTW (p=0.003) or PSM (p=0.004). Although PFS was comparable between the two groups, the TARE group showed a trend of prolonged PFS in a subpopulation of patients with Vp1 or Vp2 PVTT (p=0.052). In the matched cohorts, the ORR of the TARE group was 53.0–56.7%, whereas that of the TKI group was 12.3–15.0%.
Conclusions For patients with advanced HCC with segmental or lobar PVTT and well-preserved liver function, TARE may provide superior OS compared to sorafenib or lenvatinib.
Citations
Citations to this article as recorded by
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Ramanpreet Singh, Mina S. Makary Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis Youngsu Park, Yuri Cho, Seung Up Kim, Aryoung Kim, Hyunjae Shin, Hyo-Cheol Kim, In Joon Lee, Gyoung Min Kim, Dongho Hyun, Yunmi Ko, Jeayeon Park, Jae Woong Yoon, Gyung Sun Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Diagnostic and Interventional Imaging.2025;[Epub] CrossRef
Transarterial radioembolization challenges immunotherapy as first-line care for hepatocellular carcinoma with portal vein tumor thrombosis Anna Pellat, Maxime Barat Diagnostic and Interventional Imaging.2025;[Epub] CrossRef
Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park JHEP Reports.2024; 6(4): 100991. CrossRef
Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim Yonsei Medical Journal.2024; 65(7): 371. CrossRef
Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022 Yuri Cho, Bo Hyun Kim, Young-Suk Lim Digestive Disease Interventions.2024; 08(03): 169. CrossRef
Research Progress in Predicting Hepatocellular Carcinoma with Portal Vein Tumour Thrombus in the Era of Artificial Intelligence Yaduo Li, Ningning Fan, Xu He, Jianjun Zhu, Jie Zhang, Ligong Lu Journal of Hepatocellular Carcinoma.2024; Volume 11: 1429. CrossRef
Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report Li-Cong Liang, Wen-Sou Huang, Zhao-Xiong Guo, Hong-Ji You, Yong-Jian Guo, Ming-Yue Cai, Li-Teng Lin, Guo-Ying Wang, Kang-Shun Zhu World Journal of Gastroenterology.2024; 30(36): 4071. CrossRef
Transarterial intervention therapy combined with systemic therapy for HCC: a review of recent five-year articles Chao Fu, Hongsen Chen, Yifan Chen, Wenbin Liu, Guangwen Cao Hepatoma Research.2024;[Epub] CrossRef
The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation Kaina Chen, Aaron K.T. Tong, Fiona N.N. Moe, David C.E. Ng, Richard H.G. Lo, Apoorva Gogna, Sean X. Yan, Sue Ping Thang, Kelvin S.H. Loke, Nanda Karaddi Venkatanarasimha, Hian Liang Huang, Chow Wei Too, Timothy S.K. Ong, Eng Xuan Yeo, Daniel Yang Yao Peh, Liver Cancer.2024; : 1. CrossRef
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein throm Jin Hyoung Kim, Gun Ha Kim, Dong Il Gwon Clinical and Molecular Hepatology.2024; 30(4): 659. CrossRef
Unexpected Anti-tumor Effect of Selective Internal Radiation Therapy and Radiofrequency Ablation Followed by Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Mingzhi Hao, Hai Lan Lin, Yubin Hu, Qizhong Chen, Zhangxian Chen, Linbin Qiu, Duanyu Lin, Hui Zhang, Zuting Fang, Jingfeng Liu Hepatitis Monthly.2024;[Epub] CrossRef
Background/Aims The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy.
Methods Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed.
Results Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase.
Conclusions A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.
Citations
Citations to this article as recorded by
Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy–Induced HBsAg Seroclearance Han Ah. Lee, Hyun Woong Lee, Yeon Seok Seo, Dong Hyun Sinn, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2025; 40(7): 1675. CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients Tai-Chung Tseng, Tetsuya Hosaka, Mei-Hung Pan, Chun-Jen Liu, Fumitaka Suzuki, Chien-Jen Chen, Tung-Hung Su, Hiromitsu Kumada, Wan-Ting Yang, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Hwai-I. Yang, Jia-Horng Kao Hepatology.2025;[Epub] CrossRef
Cost‐Effectiveness of Antiviral Therapy in Patients With High Viremic Indeterminate Phase Chronic Hepatitis B Suk‐Chan Jang, Won‐Mook Choi, Gi‐Ae Kim, Gwang Hyeon Choi, Yun Bin Lee, Dong Hyun Sinn, Hye‐Lin Kim, Young‐Suk Lim Liver International.2025;[Epub] CrossRef
Comparison of the efficacy and action mechanism of Chinese patent medicines for liver fibrosis and cirrhosis Lingping Fu, Jin Xie, ZeXin Wang, Tao Jiang, Yi Zeng, Jing Yan, Rong Sun, Mengshuang Huang, Shengyi Du, Xiaobao Wang, Yuyang Liu, Kailai Xi, Ailin Chen, Xiao Ma, Jinhao Zeng, Thomas Efferth Phytomedicine.2025; 148: 157246. CrossRef
Longitudinal observation of chronic domestic cat hepadnavirus infection in cats with evidence of extrahepatic involvement Sabrina Wahyu Wardhani, Sitthichok Lacharoje, Tanit Kasantikul, Chutchai Piewbang, Somporn Techangamsuwan Journal of Feline Medicine and Surgery.2025;[Epub] CrossRef
Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”? Yen-Chun Liu, Wen-Juei Jeng Current Hepatology Reports.2024; 23(1): 11. CrossRef
Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation Jinglin Tang, Jiaxuan Zhang, Gaoli Zhang, Wenhui Peng, Ning Ling, Yingzhi Zhou, Hongmei Xu, Hong Ren, Min Chen, Marthandan Mahalingam, Swati Jain mBio.2024;[Epub] CrossRef
Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable? Shasha Ma, Lian Zhou, Shutao Lin, Mingna Li, Jing Luo, Lubiao Chen Diagnostics.2024; 14(5): 456. CrossRef
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim JHEP Reports.2024; 6(7): 101089. CrossRef
Inverse relationship between HBV DNA levels and liver histopathological changes in immune‐tolerant CHB patients Deliang Huang, Huiyi Lai, Zhibin Zhu, Hong Yu, Jinghan Peng, Yuanyuan Chen, Xuejiao Liao, Jun Chen Journal of Viral Hepatitis.2024; 31(7): 363. CrossRef
Editorial: High qHBsAg—is it a good or bad signal? Beom Kyung Kim Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616. CrossRef
Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase Jian Wang, Li Zhu, Zhiyi Zhang, Shaoqiu Zhang, Yifan Pan, Yuanyuan Li, Fei Cao, Chao Jiang, Tao Fan, Ye Xiong, Jiacheng Liu, Yuxin Chen, Shengxia Yin, Xin Tong, Chuanwu Zhu, Xingxiang Liu, Jie Li, Chao Wu, Rui Huang Virology Journal.2024;[Epub] CrossRef
Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis Min Liu, Taixue Zhao, Jinyang Zhang, Bing Bu, Ruyi Zhang, Xueshan Xia, Jiawei Geng Reviews in Medical Virology.2024;[Epub] CrossRef
Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT Menghui Duan, Huanming Xiao, Meijie Shi, Yubao Xie, Pengtao Zhao, Sheng Li, Xiaoling Chi, Xueen Liu, Hui Zhuang BMC Infectious Diseases.2024;[Epub] CrossRef
Preface Seung Up Kim Clinical and Molecular Hepatology.2024; 30(Suppl): S3. CrossRef
Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi Clinical and Molecular Hepatology.2024; 30(Suppl): S106. CrossRef
HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis Yuanyuan Li, Yijia Zhu, Dongmei Gao, Yifan Pan, Jian Wang, Shaoqiu Zhang, Xiaomin Yan, Li Zhu, Chuanwu Zhu, Xingxiang Liu, Zhaoping Zhang, Jie Li, Yuxin Chen, Rui Huang, Chao Wu Virology Journal.2024;[Epub] CrossRef
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B? Joo Hyun Oh, Dong Hyun Sinn Clinical and Molecular Hepatology.2023; 29(2): 367. CrossRef
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase” Chia-Ming Chu, Yun-Fan Liaw Clinical and Molecular Hepatology.2023; 29(2): 510. CrossRef
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2023; 29(2): 363. CrossRef
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase” Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef
Research Progress in Histological Features and Related Influencing Factors of Chronic Hepatitis B Patients with Persistent Normal ALT 宇行 刘 Advances in Clinical Medicine.2023; 13(05): 8702. CrossRef
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim Clinical and Molecular Hepatology.2023; 29(3): 779. CrossRef
Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent worldwide and becoming a major cause of liver disease-related morbidity and mortality. The presence of liver fibrosis in patients with NAFLD is closely related to prognosis, including the development of hepatocellular carcinoma and other complications of cirrhosis. Therefore, assessment of the presence of significant or advanced liver fibrosis is crucial. Although liver biopsy has been considered the “gold standard” method for evaluating the degree of liver fibrosis, it is not suitable for extensive use in all patients with NAFLD owing to its invasiveness and high cost. Therefore, noninvasive biochemical and imaging biomarkers have been developed to overcome the limitations of liver biopsy. Imaging biomarkers for the stratification of liver fibrosis have been evaluated in patients with NAFLD using different imaging techniques, such as transient elastography, shear wave elastography, and magnetic resonance elastography. Furthermore, artificial intelligence and deep learning methods are increasingly being applied to improve the diagnostic accuracy of imaging techniques and overcome the pitfalls of existing imaging biomarkers. In this review, we describe the usefulness and future prospects of noninvasive imaging biomarkers that have been studied and used to evaluate the degree of liver fibrosis in patients with NAFLD.
Citations
Citations to this article as recorded by
Visualization of the protective role of estrogen against female liver fibrosis via an ER viscosity NIR fluorescent probe Zheng Liu, Changyu Zhang, Zipeng Li, Wanying Ma, Jia Liu, Xiang Xia, Ning Xu, Wen Sun, Jianjun Du, Jiangli Fan, Xiaojun Peng Science China Chemistry.2025; 68(1): 360. CrossRef
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib Won Sohn Clinical and Molecular Hepatology.2025; 31(1): 277. CrossRef
Collagen fibers quantification for liver fibrosis assessment using linear dichroism photoacoustic microscopy Yang Qiu, Honghui Li, Kun Yu, Jiali Chen, Li Qi, Yinghua Zhao, Liming Nie Photoacoustics.2025; 42: 100694. CrossRef
Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics Gangfeng Zhu, Yipeng Song, Zenghong Lu, Qiang Yi, Rui Xu, Yi Xie, Shi Geng, Na Yang, Liangjian Zheng, Xiaofei Feng, Rui Zhu, Xiangcai Wang, Li Huang, Yi Xiang Journal of Translational Medicine.2025;[Epub] CrossRef
Neutrophil Percentage-to-Albumin Ratio and Neutrophil-to-Albumin Ratio as novel biomarkers for non-alcoholic fatty liver disease: a systematic review and meta-analysis Amr Ali Mohamed Abdelgawwad El-Sehrawy, Maryam Jafari, Ahmed Hussein Zwamel, Pegah Rashidian, Suhas Ballal, Rishiv Kalia, Anima Nanda, Laxmidhar Maharana, Sepide Javankiani, Mohammad Hashemi, Ehsan Amini-Salehi Journal of Health, Population and Nutrition.2025;[Epub] CrossRef
7-T MRI-based surrogate for histopathology examination of liver fibrosis Jérémy Dana, Antonin Fattori, Chrystelle Po, Aurélie Beaufrère, Valérie Vilgrain, Valérie Paradis, Patrick Pessaux, Thomas F. Baumert, Benoît Gallix, Aïna Venkatasamy European Radiology Experimental.2025;[Epub] CrossRef
Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities Yawei Kong, Zhengyang Chen, Zhentian Nie, Wei Chen Pharmacological Research.2025; 217: 107823. CrossRef
Associations of hepatic steatosis index in early pregnancy with perinatal outcomes: A prospective birth cohort study Shaofei Su, Enjie Zhang, Shen Gao, Yue Zhang, Jianhui Liu, Shuanghua Xie, Jinghan Yu, Qiutong Zhao, Wentao Yue, Ruixia Liu, Chenghong Yin Clinical Medicine.2025; 25(4): 100343. CrossRef
MRI findings of confluent hepatic fibrosis caused by different etiologies Dan Yu, Xiao-Hua Li, Xue-Lin He, Xi-Bin Jia, Zhen-Chang Wang, Zheng-Han Yang, A-Hong Ren BMC Gastroenterology.2025;[Epub] CrossRef
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2025;[Epub] CrossRef
Diagnostic Performance of SWE and Predictive Models Based on SWE for Post-Hepatectomy Liver Failure: A Systematic Review and Meta-analysis Jiaxu Liang, Fukun Shi, Lan Zhang, Suo Yin, Yong Chen Current Medical Imaging Formerly Current Medical Imaging Reviews.2025;[Epub] CrossRef
Randomised, controlled, crossover clinical trial protocol of puerarin for the treatment of metabolic-associated fatty liver disease in China Yu Cui, Xinrui Ren, Jiayi Song, Zhi Shang, Wanchun Zhu, Yiwen Tang, Bowu Chen, Zhuo Yu, Yueqiu Gao, Lingying Huang BMJ Open.2025; 15(9): e104364. CrossRef
Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef
Advancements and challenges of ultrasound imaging in the management of thyroid-associated ophthalmopathy Ju-Feng Shi, Wei-Yi Zhou, Hong-Xi Zhang, Ya Shen, Hang Zhang, Tuo Li World Journal of Radiology.2025;[Epub] CrossRef
Liver biopsy in the modern era: from traditional techniques to artificial intelligence and multi-omics integration Nasar Alwahaibi, Maryam Alwahaibi Frontiers in Medicine.2025;[Epub] CrossRef
The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai, Yu‐Ju Wei, Ching‐I Huang, Chih‐Wen Wang, Tyng‐Yuan Jang, Ming‐Lun Yeh, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Chia‐Yen Dai, Wan‐Long Chuang, Jee‐Fu Huang, Ming‐Lung Yu Journal of Gastroenterology and Hepatology.2024; 39(1): 193. CrossRef
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef
Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis Tamer A. Addissouky, Majeed M. A. Ali, Ibrahim El Tantawy El Sayed, Yuliang Wang The Egyptian Journal of Internal Medicine.2024;[Epub] CrossRef
The Portal Venous Pulsatility Index and Main Portal Vein Diameter as Surrogate Markers for Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Metabolic-Dysfunction-Associated Steatotic Liver Disease Jaejun Lee, Seungmyeon Choi, Seong-Hyun Cho, Hyun Yang, Pil-Soo Sung, Si-Hyun Bae Diagnostics.2024; 14(4): 393. CrossRef
TyG-GGT is a Reliable Non-Invasive Predictor of Advanced Liver Fibrosis in Overweight or Obese Individuals Lei Jin, Jing Gu, Zhe Zhang, Cheng-Fei Du, Fei-Qi Xu, Xiao-Kun Huang, Zhen-Yu Gao, Ying Li, Li-Li Yu, Xin Zhang, Guo-Qing Ru, Jun-Wei Liu, Lei Liang, Xiao-Dong Sun, Zun-Qiang Xiao Obesity Surgery.2024; 34(4): 1333. CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo Gut and Liver.2024; 18(2): 283. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; 13(5): 561. CrossRef
Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Farah Abdelhameed, Chris Kite, Lukasz Lagojda, Alexander Dallaway, Kamaljit Kaur Chatha, Surinderjeet S. Chaggar, Maria Dalamaga, Eva Kassi, Ioannis Kyrou, Harpal S. Randeva Current Obesity Reports.2024; 13(3): 510. CrossRef
Are endosonographic shear wave measurement results reliable without interquartile range median value? Fatih Albayrak, Hakan Dursun Gastrointestinal Endoscopy.2024; 100(1): 161. CrossRef
Point Shear Wave Elastography for Splenic Assessment: A Comparative Study of Splenomegaly and Normal Spleens Parag V Patil, Saksham Jain Cureus.2024;[Epub] CrossRef
Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis Shaofang Chen, Danping Zhuang, Qingyun Jia, Bing Guo, Genwen Hu Biomaterials Research.2024;[Epub] CrossRef
The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease Do Seon Song Gut and Liver.2024; 18(4): 562. CrossRef
New Biomarkers in Liver Fibrosis: A Pass through the Quicksand? Marzia Tagliaferro, Mariapaola Marino, Valerio Basile, Krizia Pocino, Gian Ludovico Rapaccini, Gabriele Ciasca, Umberto Basile, Valeria Carnazzo Journal of Personalized Medicine.2024; 14(8): 798. CrossRef
Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction‐associated steatotic liver disease Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim Alimentary Pharmacology & Therapeutics.2024; 60(8): 1051. CrossRef
Vibration-controlled transient elastography for significant fibrosis in treatment-naïve chronic hepatitis B patients: A systematic review and meta-analysis Mi Na Kim, Jihyun An, Eun Hwa Kim, Hee Yeon Kim, Han Ah Lee, Jung Hwan Yu, Young-Joo Jin, Young Eun Chon, Seung Up Kim, Dae Won Jun, Ji Won Han, Miyoung Choi Clinical and Molecular Hepatology.2024; 30(Suppl): S106. CrossRef
KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, D Clinical and Molecular Hepatology.2024; 30(Suppl): S5. CrossRef
Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease Jung Hwan Yu The Korean Journal of Medicine.2024; 99(5): 232. CrossRef
Comparing ultrasound-derived fat fraction and MRI-PDFF for quantifying hepatic steatosis: a real-world prospective study Ruixiang Qi, Liren Lu, Ting He, Liqing Zhang, Yiting Lin, Lingyun Bao European Radiology.2024; 35(5): 2580. CrossRef
Pathogenesis and management of metabolic dysfunction-associated
steatohepatitis-related hepatocellular carcinoma: a narrative
review Han Ah Lee The Ewha Medical Journal.2024;[Epub] CrossRef
Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography Han Ah Lee Clinical Ultrasound.2024; 9(2): 70. CrossRef
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang Clinical and Molecular Hepatology.2023; 29(2): 404. CrossRef
Comparison between Two-Dimensional and Point Shear Wave Elastography Techniques in Evaluating Liver Fibrosis Using Histological Staging as the Reference Standard: A Prospective Pilot Study Sang Lee, Hong Ha, In Lee, Kwanseop Lee, Jung Lee, Ji Park, Sung-Eun Kim, Mi Kwon, Ji-Young Choe, Sam-Youl Yoon, Seung-Gu Yeo, Min-Jeong Kim Diagnostics.2023; 13(9): 1646. CrossRef
The application of a novel platform of multiparametric magnetic resonance imaging in a bioenvironmental toxic carbon tetrachloride-induced mouse model of liver fibrosis Liao Qiuling, Yu Qilin, Yu Cheng, Zhang Minping, Wang Kangning, Xiao Enhua Environmental Research.2023; 238: 117130. CrossRef
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim Cell Communication and Signaling.2023;[Epub] CrossRef
Novel noninvasive indices for the assessment of liver fibrosis in primary biliary cholangitis Yan Li, Meng-Jun Zhang, Xue-Hong Wang, Su-Hua Li Biomedical Reports.2023;[Epub] CrossRef
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clin Mol Hepatol 2022;28(3):425-472. Published online July 1, 2022
The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment in nonalcoholic fatty liver disease, the beneficial effects of antidiabetics and non–antidiabetics in clinical practice have been continuously investigated in patients with CLD. In this narrative review, we focused on non-antidiabetic drugs, including ursodeoxycholic acid, silymarin, dimethyl4,4’-dimethoxy-5,6,5’,6’-dimethylenedixoybiphenyl-2,2’-dicarboxylate, L-ornithine L-aspartate, branched chain amino acids, statin, probiotics, vitamin E, and aspirin, and summarized their beneficial effects in CLD. Based on the antioxidant, anti-inflammatory properties, and regulatory functions in glucose or lipid metabolism, several non–antidiabetic drugs have shown beneficial effects in improving liver histology, aminotransferase level, and metabolic parameters and reducing risks of hepatocellular carcinoma and mortality, without significant safety concerns, in patients with CLD. Although the effect as the centerpiece management in patients with CLD is not robust, the use of these non-antidiabetic drugs might be potentially beneficial as an adjuvant or combined treatment strategy.
Citations
Citations to this article as recorded by
CYP4A14-PPARα axis serves as a therapeutic target for ursodeoxycholic acid in ameliorating high-fat diet-induced MASLD Bing Li, Pengjun Zhong, Xueling Zhang, Chengguo Li, Min Luan, Yanlin Chen, Lei Chen, Wu Li, Rihui Wu The Journal of Nutritional Biochemistry.2026; 147: 110138. CrossRef
An in vitro 3D spheroid model with liver steatosis and fibrosis on microwell arrays for drug efficacy evaluation Jiamin Chen, Ping Wang, Zhanpeng Li, Jieyi Wu, Fang Tang, Niao Yang, Bohong Cen, Cuiyin Xie, Yufan Yang, Ziyan Yang, Chuwen Zhang, Xiangcao Yao, Zhongyuan Xu Journal of Biotechnology.2025; 399: 153. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future Sunetra Mondal, Amarta Shankar Chowdhury, Rajat Deb, Debmalya Sanyal Diabetology International.2025; 16(4): 678. CrossRef
Polymer-engineered delivery systems for Schisandra lignans: A review of advances in hepatic-targeted therapy Jia Zhou, Jiyuan Zhang, Jinzhuan Xu, Man Zhang, Yuanxing Huang, Zhengli Zhou, Hexinchen Tian, Jing Huang, Jianqing Peng, Runbin Sun, Yi Chen, Zipeng Gong International Journal of Biological Macromolecules.2025; 323: 147083. CrossRef
Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’ Dong Hyun Kim, Hye Won Lee Alimentary Pharmacology & Therapeutics.2025; 62(9): 954. CrossRef
Modulation of Amomum tsao-ko on lipid metabolism and gut microbiota in high-fat diet-fed mice with NAFLD Zezhu Du, Lijun Yu, Jinya Dong, Linxian Shan, Jun He, Yan Shen, Yanmei Li, Xiuli Lu, Shengjie Duan, Jianyang Fu, Xiaocui Du, Yunfei Ge, Ruijuan Yang, Chongye Fang Journal of Agriculture and Food Research.2025; 24: 102379. CrossRef
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review Hafiza Madiha Jaffar, Fahad Al‐Asmari, Faima Atta Khan, Muhammad Abdul Rahim, Eliasse Zongo Food Science & Nutrition.2024; 12(5): 3097. CrossRef
The additive effect of herbal medicines on lifestyle modification in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis Myung-Ho Kim, Subin Ahn, Nayeon Hur, Seung-Yun Oh, Chang-Gue Son Frontiers in Pharmacology.2024;[Epub] CrossRef
Association between ursodeoxycholic acid use and COVID-19 in individuals with chronic liver disease: a nationwide case-control study in South Korea Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Virology Journal.2024;[Epub] CrossRef
Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks Amani Elshaer, Blanca C. Lizaola-Mayo Life.2024; 14(12): 1701. CrossRef
Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease Iqra J Mazhar, Mohamed Yasir, Saba Sarfraz, Gandhala Shlaghya, Sri Harsha Narayana, Ujala Mushtaq, Basim Shaman Ameen, Chuhao Nie, Daniel Nechi, Sai Sri Penumetcha Cureus.2023;[Epub] CrossRef
ALT Is Not Associated With Achieving Subcirrhotic Liver Stiffness and HCC During Entecavir Therapy in HBV-Related Cirrhosis Mi Na Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Won Young Tak, Young-Oh Kweon, Soo Young Park, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(9): 2278. CrossRef
Case 9: A 62-Year-Old Woman With Jaundice and General Weakness Hee Sun Cho, Ji Won Han, Ji Hoon Kim, Heechul Nam, Pil Soo Sung, Si Hyun Bae Journal of Korean Medical Science.2023;[Epub] CrossRef
Visión actual sobre el diagnóstico y los cuidados integrales en la encefalopatía hepática F. Higuera-de-la-Tijera, J.A. Velarde-Ruiz Velasco, R.H. Raña-Garibay, G.E. Castro-Narro, J.M. Abdo-Francis, R. Moreno-Alcántar, J.L. Pérez-Hernández, A. Torre, R. Contreras-Omaña, A. Cano-Contreras, M. Castillo-Barradas, J. Pérez-Escobar, J.M. Aldana-Led Revista de Gastroenterología de México.2023; 88(2): 155. CrossRef
Current vision on diagnosis and comprehensive care in hepatic encephalopathy F. Higuera-de-la-Tijera, J.A. Velarde-Ruiz Velasco, R.H. Raña-Garibay, G.E. Castro-Narro, J.M. Abdo-Francis, R. Moreno-Alcántar, J.L. Pérez-Hernández, A. Torre, R. Contreras-Omaña, A. Cano-Contreras, M. Castillo-Barradas, J. Pérez-Escobar, J.M. Aldana-Led Revista de Gastroenterología de México (English Edition).2023; 88(2): 155. CrossRef
Multiple Hepatic Artery Pseudoaneurysms With Eosinophilia Mun Young Cho, Pil Soo Sung, Sung Hak Lee Gastroenterology.2023; 165(4): 843. CrossRef
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim Cell Communication and Signaling.2023;[Epub] CrossRef
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen Clinical and Molecular Hepatology.2022; 28(4): 841. CrossRef
CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren International Journal of Molecular Sciences.2022; 23(24): 15931. CrossRef
Genotype–Phenotype Association in ABCC2 Exon 18 Missense Mutation Leading to Dubin–Johnson Syndrome: A Case Report Ji-Hoon Kim, Min-Woo Kang, Sangmi Kim, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung International Journal of Molecular Sciences.2022; 23(24): 16168. CrossRef
Acute kidney injury (AKI) is common in advanced cirrhosis. Prerenal azotemia, hepatorenal syndrome, and acute tubular necrosis are the main causes of AKI in patients with cirrhosis. Evaluation of renal function and differentiation between functional and structural kidney injury are important issues in the management of cirrhosis. However, AKI in cirrhosis exists as a complex clinical spectrum rather than concrete clinical entity. Based on current evidence, changes in serum creatinine (Cr) levels remain the most appropriate standard for defining AKI in cirrhosis. However, serum Cr has a limited role in assessing renal function in this population. This review examines previous studies that investigated the ability of recent biomarkers for AKI in cirrhosis from the perspective of earlier and accurate diagnosis, classification of AKI phenotype, and prediction of clinical outcomes. Serum cystatin C and urine neutrophil gelatinase-associated lipocalin have been extensively studied in cirrhosis, and have facilitated improved diagnosis and prognosis prediction in patients with AKI. In addition, urine N-acetyl-β-D-glucosaminidase, interleukin 18, and kidney injury molecule 1 are other promising biomarkers for advanced cirrhosis. However, the clinical significance of these markers remains unclear because there are no cut-off values defining the normal range and differentiating phenotypes of AKI. In addition, AKI has been defined in terms of serum Cr, and renal biopsy—the gold standard—has not been carried out in most studies. Further discovery of innovate biomarkers and incorporation of various markers could improve the diagnosis and prognosis prediction of AKI, and will translate into meaningful improvements in patient outcomes.
Citations
Citations to this article as recorded by
Evaluation of Acute Kidney Injury (AKI) Biomarkers FABP1, NGAL, Cystatin C and IL-18 in an Indian Cohort of Hospitalized Acute-on-chronic Liver Failure (ACLF) Patients Rohini Saha, Samriddhi Sharma, Antara Mondal, Hem C. Sati, Maroof A. Khan, Sandeep Mahajan, Sudip Datta, Shalimar, Pragyan Acharya Journal of Clinical and Experimental Hepatology.2025; 15(3): 102491. CrossRef
The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review Mohammed Yousef Almulhim, Gianpaolo Reboldi PLOS ONE.2025; 20(1): e0311755. CrossRef
Neutrophil gelatinase–associated lipocalin for predicting acute kidney injury in orthotopic liver transplantation: a systematic review and meta-analysis Fangran Yan, Zenghua Zhou, Xueke Du, Sheng He, Linghui Pan European Journal of Gastroenterology & Hepatology.2025; 37(6): 683. CrossRef
Understanding acute kidney injury in cirrhosis: Current perspective Sayan Malakar, Sumit Rungta, Arghya Samanta, Umair Shamsul Hoda, Piyush Mishra, Gaurav Pande, Akash Roy, Suprabhat Giri, Praveer Rai, Samir Mohindra, Uday C Ghoshal World Journal of Hepatology.2025;[Epub] CrossRef
Protective effects of Katsuwonus pelamis hydrolysates against renal injury: Val-Lys as a potent renoprotective peptide Ying Cheng, Mingjie Zhou, Zishan Hong, Lin Zheng, Mouming Zhao Food & Function.2025; 16(13): 5616. CrossRef
Acute Kidney Injury in Patients with Liver Cirrhosis: From Past to Present Definition and Diagnosis Andreea Lungu, Georgiana-Elena Sarbu, Alexandru Sebastian Cotlet, Ilie-Andreas Savin, Ioana-Roxana Damian, Simona Juncu, Cristina Muzica, Irina Girleanu, Ana-Maria Sîngeap, Carol Stanciu, Anca Trifan, Camelia Cojocariu Life.2025; 15(8): 1249. CrossRef
The Value of Diffusion Kurtosis Imaging to Assess Liver and Kidney Recovery after Mesenchymal Stem Cell Intervention in CCl4-Induced Cirrhotic Rats Jiaming Qin, Shuangshuang Xie, Yongquan Yu, Cheng Zhang, Yumeng Zhao, Dan Tong, Zhandong Hu, Jinxia Zhu, Wen Shen American Journal of Nephrology.2025; 56(4): 475. CrossRef
CIRROSE HEPÁTICA EM ESTÁGIO AVANÇADO E O PAPEL DO TRANSPLANTE DE FÍGADO: DESAFIOS ATUAIS E PERSPECTIVAS FUTURAS NO MANEJO DE PACIENTES COM DOENÇA HEPÁTICA TERMINAL Gabriel Duarte do Nascimento, Gustavo Ribeiro Mesquita, Gilson Augusto Nunes Martins Pombeiro Revista Contemporânea.2025; 5(8): e8869. CrossRef
Nationwide analysis of renal outcomes in chronic hepatitis B patients treated with Tenofovir Alafenamide vs. Entecavir Hyuk Kim, Jae Young Kim, Hye-Jin Yoo, Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim Scientific Reports.2025;[Epub] CrossRef
Delhi Model: A New Tool for Predicting Response to Terlipressin in Hepatorenal Syndrome—Acute Kidney Injury Jatin Agrawal, Ashish Kumar, Praveen Sharma, Naresh Bansal, Vikas Singla, Samarth Sharma, Anil Arora Journal of Clinical and Experimental Hepatology.2024; 14(1): 101266. CrossRef
Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim The Journal of Infectious Diseases.2024; 229(1): 108. CrossRef
VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in Cirrhosis Shohei Asada, Tadashi Namisaki, Kosuke Kaji, Hiroaki Takaya, Takahiro Kubo, Takemi Akahane, Hideto Kawaratani, Norihisa Nishimura, Soichi Takeda, Hiroyuki Masuda, Akihiko Shibamoto, Takashi Inoue, Satoshi Iwai, Fumimasa Tomooka, Yuki Tsuji, Yukihisa Fujin Digestive Diseases and Sciences.2024; 69(3): 851. CrossRef
Evaluation of Kidney Injury Using Arterial Spin Labeling and Blood Oxygen Level‐Dependent MRI: An Experimental Study in Rats With Carbon Tetrachloride‐Induced Liver Cirrhosis Jiaming Qin, Shuangshuang Xie, Yongquan Yu, Jiaqi Yang, Yumeng Zhao, Caixin Qiu, Xiaotian Li, Cheng Zhang, Zhandong Hu, Dan Tong, Jinxia Zhu, Bernd Kuehn, Wen Shen Journal of Magnetic Resonance Imaging.2024;[Epub] CrossRef
Features of the course of hepatorenal syndrome in decompensated portal hypertension (case report) M.I. Tutchenko, D.V. Rudyk, M.S. Besedinskyi, S.L. Chub, Yu.V. Nerushchenko GASTROENTEROLOGY.2024; 58(2): 151. CrossRef
Development and validation of a web-based nomogram for acute kidney injury in acute non-variceal upper gastrointestinal bleeding patients Chaolian Wei, Honghua Cao, Lina Huang, Lu-Huai Feng Frontiers in Medicine.2024;[Epub] CrossRef
Can Novel Biomarkers Effectively Predict Acute Kidney Injury in Liver or Kidney Transplant Recipients? Hubert Zywno, Wojciech Figiel, Michal Grat, Slawomir Nazarewski, Zbigniew Galazka, Jolanta Malyszko International Journal of Molecular Sciences.2024; 25(22): 12072. CrossRef
Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research? Rohan Vijay Yewale, Balakrishnan Siddartha Ramakrishna Hepatology Research.2023; 53(1): 3. CrossRef
Medication dosing in adult patients with reduced lean body mass and kidney injury: A focus on cystatin C Brian L Erstad, David E Nix American Journal of Health-System Pharmacy.2023; 80(12): 712. CrossRef
Acute kidney injury in patients with acute-on-chronic liver failure: clinical significance and management Jeong-Ju Yoo, Moo Yong Park, Sang Gyune Kim Kidney Research and Clinical Practice.2023; 42(3): 286. CrossRef
Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status Xiao Liu, Shaomin Gong, Yichun Ning, Yang Li, Huili Zhou, Luna He, Lin Lin, Shi Jin, Ziyan Shen, Bowen Zhu, Fang Li, Jie Li, Xiao Tan, Xiaoyan Jiao, Yiqin Shi, Xiaoqiang Ding BMC Nephrology.2023;[Epub] CrossRef
Hepatorenal syndrome: Current concepts and future perspectives Chan-Young Jung, Jai Won Chang Clinical and Molecular Hepatology.2023; 29(4): 891. CrossRef
Diagnostic value of combined detection of urine NGAL, KIM-1, and TFF3 in acute tubular necrosis associated with cirrhosis Yan-Qing Gong, Ying Zhao, Yan-Hui Jia, Man Li, Yong Jiang World Chinese Journal of Digestology.2023; 31(19): 808. CrossRef
Influence of fluid balance on postoperative outcomes after hepatic resection in patients with left ventricular diastolic dysfunction Jungho Shin, Suk-Won Suh Frontiers in Surgery.2022;[Epub] CrossRef
Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo
Clin Mol Hepatol 2021;27(3):463-473. Published online February 15, 2021
Background/Aims Useful biomarkers for metabolic syndrome have been insufficient. We investigated the performance of serum milk fat globule-EGF factor-8 (MFG-E8), the key mediator of inflammatory pathway, in diagnosis of metabolic syndrome.
Methods Subjects aged between 30 and 64 years were prospectively enrolled in the Seoul Metabolic Syndrome cohort. Serum MFG-E8 levels were measured at baseline.
Results A total of 556 subjects were included, comprising 279 women (50.2%) and 277 men (49.8%). Metabolic syndrome was diagnosed in 236 subjects (42.4%), and the mean MFG-E8 level of subjects with metabolic syndrome was significantly higher than that of subjects without metabolic syndrome (P<0.001). MFG-E8 level was significantly correlated with all metabolic syndrome components and pulse wave velocity (all P<0.05). Subjects were categorized into two groups according to the best MFG-E8 cut-off value as follows: group 1, MFG-E8 level <4,745.1 pg/mL (n=401, 72.1%); and group 2, MFG-E8 level ≥4,745.1 (n=155, 27.9%). At baseline, metabolic syndrome in group 2 was significantly more prevalent than in group 1 (63.9% vs. 34.2%, P<0.001). During median follow-up of 17 months, metabolic syndrome developed in 122 (38.1%) subjects among 320 subjects without it at baseline. The incidence of metabolic syndrome in group 2 was significantly higher than that in group 1 (55.4% vs. 34.5%, P=0.003). On multivariate analysis, MFG-E8 level ≥4,745.1 pg/mL was an independent predictor for diagnosis and development of metabolic syndrome after adjusting other factors (all P<0.05).
Conclusions Serum MFG-E8 level is a potent biomarker for the screening and prediction of metabolic syndrome.
Citations
Citations to this article as recorded by
Exploring the potential of MFG-E8 in neurodegenerative diseases Dan Li, Wang Rongchun, Weihong Lu, Ying Ma Critical Reviews in Food Science and Nutrition.2025; 65(28): 5565. CrossRef
Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice Volodymyr P. Tryndyak, Rose A. Willett, Zhuolin Song, Kostiantyn Dreval, Jennifer M. Hughes Hanks, Mark I. Avigan, Fred A. Wright, Frederick A. Beland, Ivan Rusyn, Igor P. Pogribny Toxicology and Applied Pharmacology.2025; 502: 117442. CrossRef
Elevated circulating HHIP levels in patients with metabolic syndrome Jingwei Lei, Yu Yang, Yerui Lai, Dongfang Liu, Cong Wang, Weiwei Xu, Ke Li, Shengbing Li, Mengliu Yang, Ling Li Biochemical and Biophysical Research Communications.2024; 736: 150877. CrossRef
Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD Rania Dagher, Paul Fogel, Jingya Wang, David Soussan, Chia-Chien Chiang, Jennifer Kearley, Daniel Muthas, Camille Taillé, Patrick Berger, Arnaud Bourdin, Cécile Chenivesse, Sylvie Leroy, Gary Anderson, Alison A. Humbles, Michel Aubier, Roland Kolbeck, Mar PLOS ONE.2022; 17(12): e0277357. CrossRef
Dae Hoe Gu, Moon Young Kim, Yeon Seok Seo, Sang Gyune Kim, Han Ah Lee, Tae Hyung Kim, Young Kul Jung, Altay Kandemir, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Clin Mol Hepatol 2018;24(3):319-330. Published online April 30, 2018
Background/Aims The most widely used method for diagnosing sarcopenia is the skeletal muscle index (SMI). Several studies have suggested that psoas muscle thickness per height (PMTH) is also effective for detecting sarcopenia and predicting prognosis in patients with cirrhosis. The aim of this study was to evaluate the optimal cutoff values of PMTH for detecting sarcopenia in cirrhotic patients.
Methods All cirrhotic patients who underwent abdominal computed tomography (CT) scan including L3 and umbilical levels for measuring SMI and transverse psoas muscle thickness, respectively, were included. Two definitions of sarcopenia were used: (1) sex-specific cutoffs of SMI (≤52.4 cm2 /m2 in men and ≤38.5 cm2 /m2 in women) for SMI-sarcopenia and (2) cutoff of PMTH (<16.8 mm/m) for PMTH-sarcopenia.
Results Six hundred fifty-three patients were included. The average age was 53.6 ± 10.2 years, and 499 patients (76.4%) were men. PMTH correlated well with SMI in both men and women (P<0.001). Two hundred forty-one (36.9%) patients met the criteria for SMI-sarcopenia. The best PMTH cutoff values for predicting SMI-sarcopenia were 17.3 mm/m in men and 10.4 mm/m in women, and these were defined as sex-specific cutoffs of PMTH (SsPMTH). The previously published cutoff of PMTH was defined as sex-nonspecific cutoff of PMTH (SnPMTH). Two hundred thirty (35.2%) patients were diagnosed with SsPMTH-sarcopenia, and 280 (44.4%) patients were diagnosed with SnPMTH-sarcopenia. On a multivariate Cox regression analysis, SsPMTH-sarcopenia (hazard ratio [HR], 1.944; 95% confidence interval [CI], 1.144–3.304; P=0.014) was significantly associated with mortality, while SnPMTH-sarcopenia was not (HR, 1.446; 95% CI, 0.861–2.431; P=0.164).
Conclusions PMTH was well correlated with SMI in cirrhotic patients. SsPMTH-sarcopenia was an independent predictor of mortality in these patients and more accurately predicted mortality compared to SnPMTH-sarcopenia.
Citations
Citations to this article as recorded by
Sarcopenia in patients receiving TIPS is independently associated with increased risk of complications and mortality Emma Vanderschueren, Philippe Meersseman, Alexander Wilmer, Vincent Vandecaveye, Evelyne Dubois, Anne Van Eldere, Jan Clerick, Jo P. Peluso, Eveline Claus, Lawrence Bonne, Chris Verslype, Geert Maleux, Wim Laleman Digestive and Liver Disease.2025; 57(2): 549. CrossRef
The prognostic significance of sarcopenia in patients treated with definitive radiotherapy: A systematic review Alexander J. Vickers, Dónal M. McSweeney, Ananya Choudhury, Jamie Weaver, Gareth Price, Alan McWilliam Radiotherapy and Oncology.2025; 203: 110663. CrossRef
Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer Murat Günaltılı, Murad Guliyev, Mehmet Cem Fidan, Zeliha Birsin, Emir Çerme, Vali Aliyev, Hamza Abbasov, Selin Cebeci, Seda Jeral, Özkan Alan, Nebi Serkan Demirci, Çiğdem Papila, Onur Erdem Şahin, Said Erkam Bıyıkoğlu, Tülin Öztürk, Berrin Papila Medicina.2025; 61(9): 1508. CrossRef
Sarcopenia in Colorectal Cancer Surgery—Minimally Invasive vs. Open Felix Merboth, Miriam Müller‐Oerlinghausen, Heiner Nebelung, Andreas Bogner, Mathieu Pecqueux, Nadja Salisch, Marius Distler, Verena Plodeck, Ralf‐Thorsten Hoffmann, Johannes Fritzmann, Jürgen Weitz, Johanna Kirchberg Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Risk factors and prediction model for sarcopenia in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt Shuyue Tuo, Jia Yuan, Ying Liu, Zhang Wen, Qiuju Ran, Yong Li, Chan Li, Quanxin Yang, Jinhai Wang, Lu Li, Shejiao Dai, Xinxing Tantai Internal and Emergency Medicine.2025;[Epub] CrossRef
Role of the psoas muscle thickness-to-height ratio in predicting pulmonary complications and 30-day mortality after liver transplantation Chuan Li, Hong-Xia Chen, Fei-Xiong Pang, Feng-Feng Liu, Ying-Zhou Zhang, Hong-Jun Liu, Xiang Nong, Yu-Ju Xu, Yan-Hua Lai Asian Journal of Surgery.2025;[Epub] CrossRef
Effect of Sarcopenia on Coronary Atherosclerotic Burden, Lesion Complexity, and Major Cardiovascular Events in Elderly Patients With Acute Coronary Syndrome: A 1-year Follow-up Study Merve Erkan, İsmet Zengin, Süleyman Bekircavuşoğlu, Dursun Topal, Turhan Bulut, Hakan Erkan Angiology.2024; 75(7): 651. CrossRef
Effects of sarcopenia on in-hospital results and mid-term follow-up in patients with coronary artery disease and COVID-19 Merve ERKAN, İsmet ZENGİN The European Research Journal.2024; 10(1): 70. CrossRef
Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis Shuyue Tuo, Yee Hui Yeo, Rachel Chang, Zhang Wen, Qiuju Ran, Longbao Yang, Qing Fan, Junxiu Kang, Jiaojiao Si, Yi Liu, Haitao Shi, Yong Li, Jia Yuan, Na Liu, Shejiao Dai, Xiaoyan Guo, Jinhai Wang, Fanpu Ji, Xinxing Tantai Clinical Nutrition.2024; 43(1): 84. CrossRef
Computed tomography-based abdominal sarcopenic indices and bio-impedance analysis-based skeletal muscle mass index in hemodialyzed patients Maiko Arao, Takahiro Yajima Clinical Nutrition ESPEN.2024; 59: 21. CrossRef
Pre-operative psoas muscle index, a surrogate for sarcopenia; as a predictor of post-esophagectomy complications Tan Yunrong, Wong Wei Jin, Hans Alexander Mahendran, Yoong Boon Koon, Shukri Jahit, Muhammad Arif Kamaruddin, Nor'Aini Anuar, Noor Aida Mat Daud Diseases of the Esophagus.2024;[Epub] CrossRef
Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis Elton Dajti, Susana G. Rodrigues, Federica Perazza, Luigi Colecchia, Giovanni Marasco, Matteo Renzulli, Giovanni Barbara, Francesco Azzaroli, Annalisa Berzigotti, Antonio Colecchia, Federico Ravaioli JHEP Reports.2024; 6(8): 101113. CrossRef
Skeletal muscle mass and quality in gout patients versus non-gout controls: A computed tomography imaging study Allyson Covello, Michael Toprover, Cheongeun Oh, Gregoire Leroy, Ada Kumar, Brian LaMoreaux, Michael Mechlin, Theodore R. Fields, Michael H. Pillinger, Fabio Becce Joint Bone Spine.2024; 91(5): 105743. CrossRef
The Impact of Sarcopenia on the Clinical Outcomes of Percutaneous Kyphoplasty in Patients With Osteoporotic Vertebral Compression Fracture: A Retrospective Cohort Study Shan Wu, Dian Zhong, Guosheng Zhao, Yang Liu, Zhenyong Ke, Yang Wang Geriatric Orthopaedic Surgery & Rehabilitation.2024;[Epub] CrossRef
Georg Schmorl Prize of the German Spine Society (DWG) 2023: the influence of sarcopenia and paraspinal muscle composition on patient-reported outcomes: a prospective investigation of lumbar spinal fusion patients with 12-month follow-up Henryk Haffer, Maximilian Muellner, Erika Chiapparelli, Yusuke Dodo, Gaston Camino-Willhuber, Jiaqi Zhu, Ek T. Tan, Matthias Pumberger, Jennifer Shue, Andrew A. Sama, Frank P. Cammisa, Federico P. Girardi, Alexander P. Hughes European Spine Journal.2024; 33(5): 1737. CrossRef
Diffusion-tensor magnetic resonance imaging as a non-invasive assessment of extracellular matrix remodeling in lumbar paravertebral muscles of rats with sarcopenia Xin-Chen Huang, Ji-Yao Ma, Chao Gao, Jia-Xin Chen, Chun-Li Li, Yi-Long Huang, Bo He BMC Musculoskeletal Disorders.2024;[Epub] CrossRef
The cross-sectional area of gluteal muscle on multiaxial CT scan as a predictor for diagnosing sarcopenia in patients with degenerative lumbar disease Dae-Woong Ham, Jeuk Lee, GilWon Choi, Byung-Taek Kwon, Kwang-Sup Song European Spine Journal.2024; 33(10): 3857. CrossRef
The impact of appendicular skeletal muscle index and trunk muscle index on stress urinary incontinence risk in female adults: a retrospective study Junwei Wang, Cunming Zhang, Aiwei Zhang Frontiers in Nutrition.2024;[Epub] CrossRef
Psoas muscle index in sarcopenia following transjugular intrahepatic portosystemic shunt: A multicenter, retrospective study Tongqiang Li, Ze Wang, Yang Liu, Liguo Dai, Xiaoli Zhu, Jiacheng Liu, Qikun Guo, Weijie Luo, Yaowei Bai, Wei Luo, Menglan Chu, Duiping Feng, Bin Xiong Portal Hypertension & Cirrhosis.2024; 3(4): 173. CrossRef
Lumbar Magnetic Resonance Imaging Shows Sex-Specific Alterations During Musculoskeletal Aging—A Radio-Anatomic Investigation Involving 202 Individuals Horst Balling, Boris Michael Holzapfel, Wolfgang Böcker, Dominic Simon, Paul Reidler, Joerg Arnholdt Journal of Clinical Medicine.2024; 13(23): 7233. CrossRef
Psoas Muscle Index as a Predictor of Perioperative Outcomes in Geriatric Patients Undergoing Spine Surgery Mark N. Pernik, William H. Hicks, Omar S. Akbik, Madelina L. Nguyen, Ivan Luu, Jeffrey I. Traylor, Palvasha R. Deme, Luke J. Dosselman, Kristen Hall, Sarah A. Wingfield, Salah G. Aoun, Carlos A. Bagley Global Spine Journal.2023; 13(7): 2016. CrossRef
A Comparative Analysis of Frailty, Disability, and Sarcopenia With Patient Characteristics and Outcomes in Adult Spinal Deformity Surgery Omar S. Akbik, Nadeem Al-Adli, Mark N. Pernik, William H. Hicks, Kristen Hall, Salah G. Aoun, Carlos A. Bagley Global Spine Journal.2023; 13(8): 2345. CrossRef
Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions Edgewood R. Warner II, Sanjaya K. Satapathy Journal of Clinical and Experimental Hepatology.2023; 13(1): 162. CrossRef
Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol Florian Huemer, Stefan Hecht, Bernhard Scharinger, Verena Schlintl, Gabriel Rinnerthaler, Konstantin Schlick, Ronald Heregger, Thomas Melchardt, Angela Wimmer, Iris Mühlbacher, Oliver Owen Koch, Daniel Neureiter, Eckhard Klieser, Sara Seyedinia, Mohsen Be Journal of Cancer Research and Clinical Oncology.2023; 149(7): 3051. CrossRef
Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy Maximilian Thormann, Franziska Heitmann, Vanessa Wrobel, Felix Barajas Ordonez, Maciej Pech, Alexey Surov, Robert Damm, Jazan Omari RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.2023; 195(03): 217. CrossRef
Psoas Muscle Index: A Simple and Reliable Method of Sarcopenia Assessment on Computed Tomography Scan in Chronic Liver Disease and its Impact on Mortality Gajanan A. Rodge, Usha Goenka, Surabhi Jajodia, Rachit Agarwal, Shivaraj Afzalpurkar, Akash Roy, Mahesh K. Goenka Journal of Clinical and Experimental Hepatology.2023; 13(2): 196. CrossRef
Robotic Esophagectomy Compared With Open Esophagectomy Reduces Sarcopenia within the First Postoperative Year: A Propensity Score-Matched Analysis Felix Merboth, Heiner Nebelung, Natalie Wotschel, Hendrik Liebscher, Franziska Eckert, Janusz von Renesse, Jasmin Hasanovic, Thilo Welsch, Johannes Fritzmann, Daniel E. Stange, Verena Plodeck, Ralf-Thorsten Hoffmann, Marius Distler, Jürgen Weitz, Johanna Journal of Thoracic Oncology.2023; 18(2): 232. CrossRef
Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis” Do Seon Song, U Im Chang, Jin Mo Yang Clinical and Molecular Hepatology.2023; 29(1): 165. CrossRef
Sarcopenia Defined by Psoas Muscle Thickness Predicts Mortality After Transjugular Intrahepatic Portosystemic Shunt Tongqiang Li, Jiacheng Liu, Jianbo Zhao, Yaowei Bai, Songjiang Huang, Chongtu Yang, Yingliang Wang, Chen Zhou, Chaoyang Wang, Shuguang Ju, Yang Chen, Wei Yao, Bin Xiong Digestive Diseases and Sciences.2023; 68(4): 1641. CrossRef
Musculus psoas major morphology - a novel predictor of mortality in elderly polytraumatized patients Gregor Wollner, Valerie Weihs, Stephan Frenzel, Silke Aldrian, Lukas Leopold Negrin BMC Emergency Medicine.2023;[Epub] CrossRef
Sarcopenia is an independent risk factor for failure to achieve the 1-year MCID of the KOOS, JR and PROMIS PF-SF10a after TKA Tyler J. Humphrey, Mehdi S. Salimy, Jeffrey M. Jancuska, Cameron R. Egan, Christopher M. Melnic, Kyle Alpaugh, Hany S. Bedair The Knee.2023; 42: 64. CrossRef
Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics Mauro Grova, Federica Crispino, Marcello Maida, Alessandro Vitello, Sara Renna, Angelo Casà, Lorenzo Tesè, Fabio Salvatore Macaluso, Ambrogio Orlando Digestive and Liver Disease.2023; 55(7): 865. CrossRef
Korean Working Group on Sarcopenia Guideline: Expert Consensus on Sarcopenia Screening and Diagnosis by the Korean Society of Sarcopenia, the Korean Society for Bone and Mineral Research, and the Korean Geriatrics Society Ji Yeon Baek, Hee-Won Jung, Kyoung Min Kim, Miji Kim, Clara Yongjoo Park, Kwang-Pyo Lee, Sang Yoon Lee, Il-Young Jang, Ok Hee Jeon, Jae-Young Lim Annals of Geriatric Medicine and Research.2023; 27(1): 9. CrossRef
Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease Takushi Manabe, Chikara Ogawa, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Mitsushige Shibatoge, Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki Diagnostics.2023; 13(7): 1245. CrossRef
Visceral Fat as a Risk Factor for Periprosthetic Joint Infection After Total Hip and Knee Arthroplasty Amy Z. Blackburn, Akhil Katakam, Thomas Roberts, Tyler J. Humphrey, Mehdi S. Salimy, Cameron R. Egan, Christopher M. Melnic, Hany S. Bedair The Journal of Arthroplasty.2023; 38(9): 1839. CrossRef
Physical activity in sarcopenia: rehabilitation approaches in prevention and treatment of age-related muscle disorders N.V. Polenova, Yu.R. Varaeva, I.V. Pogonchenkova, E.N. Livantsova, A.M. Shchikota, N.N. Shaposhnikova, T.D. Kiknadze, A.V. Starodubova Problems of Balneology, Physiotherapy and Exercise Therapy.2023; 100(2): 52. CrossRef
A Prospective Study of Prevalence and Impact of Sarcopenia on Short-term Mortality in Hospitalized Patients with Liver Cirrhosis Surakshith Thyloor Kenchappa, Samarth Sharma, Mandhir Kumar, Samarjit S. Ghuman, Anil Arora, Piyush Ranjan Journal of Clinical and Experimental Hepatology.2023; 13(6): 946. CrossRef
Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease Alessandra Musio, Federica Perazza, Laura Leoni, Bernardo Stefanini, Elton Dajti, Renata Menozzi, Maria Letizia Petroni, Antonio Colecchia, Federico Ravaioli International Journal of Molecular Sciences.2023; 24(8): 7517. CrossRef
Osteosarcopenia in the Spine Beyond Bone Mineral Density Henryk Haffer, Maximilian Muellner, Erika Chiapparelli, Yusuke Dodo, Jiaqi Zhu, Yi Xin Han, Eve Donnelly, Ek T. Tan, Jennifer Shue, Andrew A. Sama, Frank P. Cammisa, Federico P. Girardi, Alexander P. Hughes Spine.2023; 48(14): 984. CrossRef
Determinants of Treatment Toxicity in Patients with Soft Tissue Sarcomas Katja A. Schönenberger, Emilie Reber, Karin Schläppi, Annic Baumgartner, Zeno Stanga, Attila Kollár Nutrition and Cancer.2023; 75(8): 1638. CrossRef
Sarcopenia assessments as predictors of overall survival in patients with metastatic renal cell carcinoma Luca Kümmerl, Matthias Kraulich, Wladimir Lesyuk, Adrian Binninger, Peter J. Goebell, Andreas Kahlmeyer Urologic Oncology: Seminars and Original Investigations.2023; 41(9): 392.e1. CrossRef
Sarcopenia in Chronic Liver Disease Kwang Il Seo The Korean Journal of Gastroenterology.2023; 82(5): 233. CrossRef
Reference for normal measurements of psoas muscle among the adult population in Saudi Arabia Mohammad Abdulrahim Wazzan Saudi Journal for Health Sciences.2023; 12(3): 222. CrossRef
Automated major psoas muscle volumetry in computed tomography using machine learning algorithms Felix Duong, Michael Gadermayr, Dorit Merhof, Christiane Kuhl, Philipp Bruners, Sven H. Loosen, Christoph Roderburg, Daniel Truhn, Maximilian F. Schulze-Hagen International Journal of Computer Assisted Radiology and Surgery.2022; 17(2): 355. CrossRef
Preoperative optimization of geriatric and frail patients Sher-Lu Pai, Adam K. Jacob, R. Doris Wang International Anesthesiology Clinics.2022; 60(1): 33. CrossRef
Association Between Sarcopenia and Adverse Events Following Transcatheter Aortic Valve Implantation Andrew D. Brown, Ben Li, Samantha Gabriel, Robert J. Cusimano, Jennifer Chung, Eric Horlick, Mark D. Osten, Maral Ouzounian, Graham Roche-Nagle CJC Open.2022; 4(2): 173. CrossRef
Brain CT can predict low lean mass in the elderly with cognitive impairment: a community-dwelling study Yun-Ting Chen, Chiun-Chieh Yu, Yu-Ching Lin, Shan-Ho Chan, Yi-Yun Lin, Nai-Ching Chen, Wei-Che Lin BMC Geriatrics.2022;[Epub] CrossRef
Sarcopenia is highly prevalent in children with autoimmune liver diseases and is linked to visceral fat and parent‐perceived general health Antoinette A. Amevor, Toshifumi Yodoshi, Andrew T. Trout, Jonathan R. Dillman, Ruchi Singh, Ryan Jarvis, Lin Fei, Chunyan Liu, Amy Taylor, Alexander Miethke, Marialena Mouzaki Liver International.2022; 42(2): 394. CrossRef
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis Xinxing Tantai, Yi Liu, Yee Hui Yeo, Michael Praktiknjo, Ezequiel Mauro, Yuhei Hamaguchi, Cornelius Engelmann, Peng Zhang, Jae Yoon Jeong, Jeroen Laurens Ad van Vugt, Huijuan Xiao, Huan Deng, Xu Gao, Qing Ye, Jiayuan Zhang, Longbao Yang, Yaqin Cai, Yixin Journal of Hepatology.2022; 76(3): 588. CrossRef
Predictors of Sarcopenia in an Obese Asian Population Min Je Sung, Jun Yong Park, Hye Won Lee, Beom Kyung Kim, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Nutrition and Cancer.2022; 74(2): 505. CrossRef
Older cancer patients receiving radiotherapy: a systematic review for the role of sarcopenia in treatment outcomes Nezahat Muge Catikkas, Zumrut Bahat, Meryem Merve Oren, Gulistan Bahat Aging Clinical and Experimental Research.2022; 34(8): 1747. CrossRef
Use of computed tomography for the diagnosis of surgical sarcopenia: Review of recent research advances Yu Xiao, Zhou Xiao‐yue, Wu Yue, Liu Ruo‐tao, Li Xiang‐jie, Wang Xing‐yuan, Wang Qian, Qian Xiao‐hua, Jia Zhen‐yi Nutrition in Clinical Practice.2022; 37(3): 583. CrossRef
Sarcopenia at Abdominal CT in Patients with Cirrhosis James T. Lee Radiology.2022; 303(3): 720. CrossRef
Comparison of muscle fat fraction measurements in the lower spine musculature with non-contrast-enhanced CT and different MR imaging sequences Patrick Trueb, Jonas M. Getzmann, Emanuel Ried, Eva Deininger-Czermak, Helena I. Garcia Schueler, Roman Guggenberger European Journal of Radiology.2022; 150: 110260. CrossRef
Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song Clinical and Molecular Hepatology.2022; 28(2): 219. CrossRef
Psoas muscle measurement as a marker of sarcopenia predicts risk of Grade 4 or 5 baseline chronic kidney disease and its progression Davine Yang, Sameena Iqbal, Khashayar Rafatzand, Celena Scheede‐Bergdahl JCSM Rapid Communications.2022; 5(2): 182. CrossRef
Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Mira Kang, Eliseo Guallar, Yun Soo Hong, Kyung Hyun Lee, Jiyeon Park, Juhee Cho, Geum‐Youn Gwak Hepatology.2022; 76(6): 1746. CrossRef
Primary Tumor Fluorine‐18 Fluorodeoxydglucose (18F‐FDG) Is Associated With Cancer-Associated Weight Loss in Non-Small Cell Lung Cancer (NSCLC) and Portends Worse Survival Santiago Olaechea, Bhavani S. Gannavarapu, Christian Alvarez, Anne Gilmore, Brandon Sarver, Donglu Xie, Rodney Infante, Puneeth Iyengar Frontiers in Oncology.2022;[Epub] CrossRef
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments Saeid Mirzai, Brendan L. Eck, Po-Hao Chen, Jerry D. Estep, W.H. Wilson Tang Circulation: Heart Failure.2022;[Epub] CrossRef
Effect of Preoperative Sarcopenia, Malnutrition and Functional status on Postoperative Morbidity Following Liver Transplantation Kelika Prakash, Amal Francis Sam, Nandakumar K, Neha Tandon Progress in Transplantation.2022; 32(4): 345. CrossRef
Radiological psoas muscle parameters as a reliable tool for detection of sarcopenia and prediction of short-term survival in liver cirrhosis V. M. Motsiuk, N. O. Pentiuk Reports of Morphology.2022; 28(3): 5. CrossRef
Sarcopenia in children with chronic liver disease: Prevalence and impact on liver transplant outcomes Silvio Veraldi, Andrea Pietrobattista, Giovanna Soglia, Lidia Monti, Tommaso Alterio, Antonella Mosca, Daniela Liccardo, Maria Sole Basso, Claudia Della Corte, Luca Russo, Manila Candusso, Fabrizio Chiusolo, Francesca Tortora, Marco Spada, Giuseppe Maggio Frontiers in Pediatrics.2022;[Epub] CrossRef
Development and external validation of DISPAIR fistula risk score for clinically relevant postoperative pancreatic fistula risk after distal pancreatectomy Akseli Bonsdorff, Poya Ghorbani, Ilkka Helanterä, Timo Tarvainen, Tea Kontio, Hanna Belfrage, Jukka Sirén, Arto Kokkola, Ernesto Sparrelid, Ville Sallinen British Journal of Surgery.2022; 109(11): 1131. CrossRef
Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver Pankaj Puri, Radha K. Dhiman, Sunil Taneja, Puneeta Tandon, Manuela Merli, Anil C. Anand, Anil Arora, Subrat K. Acharya, Jaya Benjamin, Yogesh K. Chawla, Sunil Dadhich, Ajay Duseja, C.E. Eapan, Amit Goel, Naveen Kalra, Dharmesh Kapoor, Ashish Kumar, Kaush Journal of Clinical and Experimental Hepatology.2021; 11(1): 97. CrossRef
Serial Observations of Muscle and Fat Mass as Prognostic Factors for Deceased Donor Liver Transplantation Jisun Lee, Woo Kyoung Jeong, Jae-Hun Kim, Jong Man Kim, Tae Yeob Kim, Gyu Seong Choi, Choon Hyuck David Kwon, Jae-Won Joh, Sang-Yong Eom Korean Journal of Radiology.2021; 22(2): 189. CrossRef
Clinical impact of sarcopenia assessment in patients with liver cirrhosis Giovanni Marasco, Elton Dajti, Federico Ravaioli, Stefano Brocchi, Benedetta Rossini, Luigina Vanessa Alemanni, Giuliano Peta, Laura Bartalena, Rita Golfieri, Davide Festi, Antonio Colecchia, Matteo Renzulli Expert Review of Gastroenterology & Hepatology.2021; 15(4): 377. CrossRef
Imaging Software‐Based Sarcopenia Assessment in Gastroenterology: Evolution and Clinical Meaning Giovanni Marasco, Sinan Sadalla, Giulio Vara, Rita Golfieri, Davide Festi, Antonio Colecchia, Matteo Renzulli, Tatsuo Kanda Canadian Journal of Gastroenterology and Hepatology.2021;[Epub] CrossRef
Definition of Sarcopenia in Chronic Liver Disease Seong Wan Son, Do Seon Song, U Im Chang, Jin Mo Yang Life.2021; 11(4): 349. CrossRef
Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites Jin Wook Lee, Jae Seok Hwang, Woo Jin Chung, Heon Ju Lee, Jung Gil Park, Chang Hyeong Lee, Byung Seok Kim, Jeong Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Byoung Kuk Jang, Bhagwan Dass PLOS ONE.2021; 16(6): e0253886. CrossRef
Usefulness of computed tomography-measured psoas muscle thickness per height for predicting mortality in patients undergoing hemodialysis Takahiro Yajima, Maiko Arao, Kumiko Yajima, Hiroshi Takahashi Scientific Reports.2021;[Epub] CrossRef
Adverse muscle composition predicts all‐cause mortality in the UK Biobank imaging study Jennifer Linge, Mikael Petersson, Mikael F. Forsgren, Arun J. Sanyal, Olof Dahlqvist Leinhard Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 1513. CrossRef
Value of the controlling nutritional status score and psoas muscle thickness per height in predicting prognosis in liver transplantation Xing Dai, Ben Gao, Xin-Xin Zhang, Jiang Li, Wen-Tao Jiang World Journal of Clinical Cases.2021; 9(35): 10871. CrossRef
Low psoas muscle index as an unfavorable factor in children with end‐stage liver disease undergoing liver transplantation Settapong Jitwongwai, Chatmanee Lertudomphonwanit, Thitiporn Junhasavasdikul, Praman Fuangfa, Pornthep Tanpowpong, Goragoch Gesprasert, Suporn Treepongkaruna Pediatric Transplantation.2021;[Epub] CrossRef
The assessment of sarcopenia using psoas muscle thickness per height is not predictive of post-operative complications in IBD Omeed Alipour, Vivian Lee, Tapas K. Tejura, Melissa Lee Wilson, Zoe Memel, Jaehoon Cho, Kyle Cologne, Caroline Hwang, Ling Shao Scandinavian Journal of Gastroenterology.2021; 56(10): 1175. CrossRef
Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis Han Ah Lee, Joon Young Jung, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyonggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um, Yeon Seok Seo Gut and Liver.2021; 15(4): 599. CrossRef
Prevalence and Nonpharmacological Interventions for Sarcopenia among Cirrhotic Patients Walid Kamal Abdelbasset, Gopal Nambi, Shereen H. Elsayed, Samah A. Moawd, Ahmed A. Ibrahim, Anju Verma, Sayed A. Tantawy, Dalia M. Kamel, Ayman K. Saleh, Osama R. Aldhafian, Naif Bin Nwihadh, Zhengwen Liu Disease Markers.2021; 2021: 1. CrossRef
Quantification of skeletal muscle mass: sarcopenia as a marker of overall health in children and adults Leah A. Gilligan, Alexander J. Towbin, Jonathan R. Dillman, Elanchezhian Somasundaram, Andrew T. Trout Pediatric Radiology.2020; 50(4): 455. CrossRef
Age-related degeneration of the lumbar paravertebral muscles: Systematic review and three-level meta-regression A. Dallaway, C. Kite, C. Griffen, M. Duncan, J. Tallis, D. Renshaw, J. Hattersley Experimental Gerontology.2020; 133: 110856. CrossRef
Novel Insights into the Pathogenesis of Spinal Sarcopenia and Related Therapeutic Approaches: A Narrative Review Yu-Kai Kuo, Yu-Ching Lin, Ching-Yu Lee, Chih-Yu Chen, Jowy Tani, Tsung-Jen Huang, Hsi Chang, Meng-Huang Wu International Journal of Molecular Sciences.2020; 21(8): 3010. CrossRef
Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study Jung Gil Park, Won Young Tak, Soo Young Park, Young Oh Kweon, Woo Jin Chung, Byoung Kuk Jang, Si Hyun Bae, Heon Ju Lee, Jae Young Jang, Ki Tae Suk, Myung Jin Oh, Jeong Heo, Hyun Young Woo, Se Young Jang, Yu Rim Lee, June Sung Lee, Do Young Kim, Seok Hyun Nutrients.2020; 12(5): 1429. CrossRef
Survival Outcomes According to Body Mass Index in Hepatocellular Carcinoma Patient: Analysis of Nationwide Cancer Registry Database Boram Cha, Jung Hwan Yu, Young-Joo Jin, Young Ju Suh, Jin-Woo Lee Scientific Reports.2020;[Epub] CrossRef
Tongue thickness in health vs cirrhosis of the liver: Prospective observational study Manish Tandon, Harshita Singh, Nishant Singla, Priyanka Jain, Chandra Kant Pandey World Journal of Gastrointestinal Pharmacology and Therapeutics.2020; 11(3): 59. CrossRef
mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI Caroline Raab, Leah A. Gilligan, Andrew T. Trout, Darcy A. Krueger, David N. Franz, Bin Zhang, Alexander J. Towbin Radiology: Imaging Cancer.2020; 2(5): e190091. CrossRef
Impact of Sarcopenia on Survival in Patients With Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy James M Taylor, Andrew Song, Allison R David, Victor E Chen, Bo Lu, Maria Werner-Wasik Cureus.2020;[Epub] CrossRef
Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study Ji Hyun Kim, Seong Hee Kang, Minjong Lee, Gi Soo Youn, Tae Suk Kim, Baek Gyu Jun, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi, Ki Tae Suk Cancers.2020; 12(11): 3347. CrossRef
Large-scale analysis of iliopsoas muscle volumes in the UK Biobank Julie A. Fitzpatrick, Nicolas Basty, Madeleine Cule, Yi Liu, Jimmy D. Bell, E. Louise Thomas, Brandon Whitcher Scientific Reports.2020;[Epub] CrossRef
Usefulness of Psoas Muscle Cross-Sectional Area in Evaluating Physical Performance in Patients with Liver Cirrhosis Bo Seong Jang, Han Eum Choi, Jae Hyun Lee, Young Joo Sim, Ghi Chan Kim, Ho Joong Jeong Kosin Medical Journal.2020; 35(2): 133. CrossRef
Sarcopenia Is a New Risk Factor of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease Min Kyu Kang, Kyeong Ok Kim, Min Cheol Kim, Jung Gil Park, Byung Ik Jang Digestive Diseases.2020; 38(6): 507. CrossRef
Sarcopenia: revised European consensus on definition and diagnosis Alfonso J Cruz-Jentoft, Gülistan Bahat, Jürgen Bauer, Yves Boirie, Olivier Bruyère, Tommy Cederholm, Cyrus Cooper, Francesco Landi, Yves Rolland, Avan Aihie Sayer, Stéphane M Schneider, Cornel C Sieber, Eva Topinkova, Maurits Vandewoude, Marjolein Visser, Age and Ageing.2019; 48(1): 16. CrossRef
Predicting Future Complications of Cirrhosis Joel Wedd, Kavitha Nair Current Hepatology Reports.2019; 18(1): 9. CrossRef
Association of loss of muscle mass with mortality in liver cirrhosis without or before liver transplantation Ke-Vin Chang, Jin-De Chen, Wei-Ting Wu, Kuo-Chin Huang, Der-Sheng Han Medicine.2019; 98(9): e14373. CrossRef
Anthropometric measures associated with sarcopenia in outpatients with liver cirrhosis Lívia A.A. Santos, Talles B. Lima, Marjorie do Val Ietsugu, Hélio R. de Carvalho Nunes, Xingshun Qi, Fernando G. Romeiro Nutrition & Dietetics.2019; 76(5): 613. CrossRef
The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis Rafael Paternostro, Katharina Lampichler, Constanze Bardach, Ulrika Asenbaum, Clara Landler, David Bauer, Mattias Mandorfer, Remy Schwarzer, Michael Trauner, Thomas Reiberger, Arnulf Ferlitsch Liver International.2019; 39(12): 2374. CrossRef
Muscle psoas indices measured by ultrasound in cirrhosis — Preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality Andrej Hari, Annalisa Berzigotti, Borut Štabuc, Nina Caglevič Digestive and Liver Disease.2019; 51(11): 1502. CrossRef
Controversies in Diagnosing Sarcopenia in Cirrhosis—Moving from Research to Clinical Practice Marie Sinclair Nutrients.2019; 11(10): 2454. CrossRef
Prognostic implications of trunk muscle mass in liver cirrhosis Jimin Han, Won Kim Clinical and Molecular Hepatology.2018; 24(3): 297. CrossRef
Background/Aims Little is known about the effect of early flares on response during first-line tenofovir disoproxil fumarate (TDF) treatment for chronic hepatitis B (CHB). The aim of this study was to investigate the incidence and outcome of early alanine aminotransferase (ALT) flare in treatment-naive patients with CHB during long-term TDF monotherapy. Methods: One hundred eighty-one treatment-naive CHB patients were treated with a 300-mg once-daily dose of TDF for more than 12 weeks. Virological markers of hepatitis B virus (HBV) and biochemical data were measured at baseline and every 4-12 weeks during the therapy. The proportion of patients with undetectable HBV DNA level (< 100 copies/mL) was noted. Results: The median age was 48.3 years and 122 patients (67.4%) were men. Hepatitis B envelope antigen (HBeAg) was positive in 101 patients (55.8%). No patient had cirrhosis. The median follow-up duration was 45 weeks (12-155 weeks). ALT flare (>5 × upper limit of the normal range) occurred in seven patients (3%) without viral breakthrough within the first 8 weeks after the start of TDF monotherapy. Among them, six patients were HBeAg-positive and one patient was HBeAg-negative. All cases of early ALT flares resolved within 4 weeks and virologic response was observed in all patients without interruption or discontinuation of treatment. Conclusions: Continuous TDF monotherapy was effective and safe in treatment-naive patients with CHB who experienced early ALT flares followed by a decrease in HBV DNA level.
Citations
Citations to this article as recorded by
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsun Clinical and Molecular Hepatology.2024; 30(2): 191. CrossRef
DFT, molecular docking and ADME prediction of tenofovir drug as a promising therapeutic inhibitor of SARS-CoV-2 Mpro Siyamak Shahab, Masoome Sheikhi, Maksim Khancheuski, Hooriye Yahyaei, Hora Alhosseini Almodarresiyeh, Sadegh Kaviani Main Group Chemistry.2023; 22(1): 115. CrossRef
Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers Jung Hun Kim, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo, Eileen L. Yoon, Seong Hee Kang Antimicrobial Agents and Chemotherapy.2022;[Epub] CrossRef
Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy Michel Bazinet, Victor Pântea, Gheorghe Placinta, Iurie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatiana Musteata, Alina Jucov, Ulf Dittmer, Adalbert Krawczyk, Andrew Vaillant Journal of Viral Hepatitis.2021; 28(5): 817. CrossRef
Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure Andrew Vaillant Viruses.2021; 13(5): 745. CrossRef
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial Man-Fung Yuen, Xue Zhou, Edward Gane, Christian Schwabe, Tawesak Tanwandee, Sheng Feng, Yuyan Jin, Miriam Triyatni, Annabelle Lemenuel-Diot, Valerie Cosson, Zenghui Xue, Remi Kazma, Qingyan Bo The Lancet Gastroenterology & Hepatology.2021; 6(9): 723. CrossRef
Tenofovir disoproxil fumarate-induced severe liver injury in a patient with chronic hepatitis B virus infection Min Kyu Kang, Jung Gil Park Digestive and Liver Disease.2018; 50(6): 628. CrossRef
Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign? Nae-Yun Heo Clinical and Molecular Hepatology.2017; 23(2): 125. CrossRef
Sang Jung Park, Yong Kwon Kim, Yeon Seok Seo, Seung Woon Park, Han Ah Lee, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jae Young Jang, Jong Eun Yeon, Kwan Soo Byun
Clin Mol Hepatol 2016;22(4):487-494. Published online December 25, 2016
Background/Aims Practice guidelines recommend endoscopic band ligation (EBL) and endoscopic variceal obturation (EVO) for bleeding from esophageal varices and fundal varices, respectively. However, the optimal treatment for bleeding from cardiac varices along the lesser curvature of the stomach (GOV1) remains undefined. This retrospective study compared the efficacy between EBL and EVO for bleeding from GOV1.
Methods Patients treated by EBL or EVO via cyanoacrylate injection for bleeding from GOV1 were enrolled. Patients diagnosed with hepatocellular carcinoma or treated with endoscopic injection sclerotherapy were excluded.
Results The study included 91 patients treated for bleeding from GOV1. The mean age was 56.3±10.9 years (mean±SD), and 78 of them (85.7%) were men. Overall, 51 and 40 patients were treated with EBL and EVO, respectively. A trend for a higher hemostasis rate was noted in the EVO group (100%) than in the EBL group (82.6%, P=0.078). Varices rebled in 15 patients during follow-up. The rebleeding rate was significantly higher in the EBL group than in the EVO group (P=0.004). During follow-up, 13 patients died (11 in the EBL group and 2 in the EVO group); the survival rate was marginally significant between two groups (P=0.050). The rebleeding-free survival rate was significantly higher in the EVO group than in the EBL group (P=0.001).
Conclusions Compared to EBL, EVO offered significantly lower rebleeding rates, significantly higher rebleeding-free survival rates, and a trend for higher hemostasis and survival rates. EVO appears to be the better therapeutic option for bleeding from GOV1.
Citations
Citations to this article as recorded by
Short-term efficacy and safety of endoscopic injection of low dose of sclerotherapy and cyanoacrylate injection for type GOV1 gastric varices combined with endoscopic variceal ligation for esophageal varices Tingting Zhang, Chuangyang Xin, Xueyun Guo, Sihai Chen, Xuelian Zheng, Wen Xu, Dongjing Zhang, Biming Li, Ye Chen, Xuan Zhu, Anjiang Wang Surgical Endoscopy.2025; 39(1): 280. CrossRef
Emergency Plug-Assisted Retrograde Transvenous Obliteration for Active Bleeding from Ruptured Gastric Varices Eunbyeol Ko, Jeongyeon Kim, Dong Il Gwon, Hee Ho Chu, Gun Ha Kim, Gi-Young Ko Journal of Vascular and Interventional Radiology.2025; 36(6): 994. CrossRef
A randomized controlled trial comparing large-volume band ligator and cyanoacrylate injection in the endoscopic management of actively bleeding gastric varices Ding Shi, Guojing Xu, Weijin Pan Scientific Reports.2025;[Epub] CrossRef
Evaluation of the efficacy and safety of endoscopic band ligation in the treatment of bleeding from mild to moderate gastric varices type 1 Yue Deng, Ya Jiang, Tong Jiang, Ling Chen, Hai-Jun Mou, Bi-Guang Tuo, Guo-Qing Shi World Journal of Gastroenterology.2024; 30(5): 440. CrossRef
Gastric variceal obstruction improves the efficacy of endoscopic management of esophageal variceal bleeding in GOV type I Xiaoquan Huang, Detong Zou, Huishan Wang, Wei Chen, Lili Zhang, Feng Li, Lili Ma, Chunqing Zhang, Ying Chen, Shiyao Chen Endoscopy International Open.2024; 12(08): E940. CrossRef
Aluminum phosphate gel reduces early rebleeding in cirrhotic patients with gastric variceal bleeding treated with histoacryl injection therapy Hao-Tian Zeng, Zhu-Liang Zhang, Xi-Min Lin, Min-Si Peng, Li-Sheng Wang, Zheng-Lei Xu World Journal of Gastrointestinal Endoscopy.2023; 15(3): 153. CrossRef
A case report of an endoscopic approach to life‐threatening cecal variceal hemorrhage Kirsty E MacFarlane, Nicholas J Fischer JGH Open.2022; 6(4): 277. CrossRef
Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis Han Ah Lee, Jungwon Kwak, Sung Bum Cho, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Seung Up Kim, Hyonggin An, Hyung Joon Yim, Jong Eun Yeon, Yeon Seok Seo BMC Gastroenterology.2022;[Epub] CrossRef
Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis Min Kyung Park, Yun Bin Lee The Korean Journal of Gastroenterology.2021; 78(3): 152. CrossRef
Endoscopic Removal of Inflated Transected Sengstaken–Blakemore Tube Using Endoscopic Scissors Jun Ho Lee, Eu-Kwon Hwang, Chanmesa Doeun, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim Clinical Endoscopy.2019; 52(2): 182. CrossRef
Prevention and management of gastroesophageal varices Yeon Seok Seo Clinical and Molecular Hepatology.2018; 24(1): 20. CrossRef
The Choice of Interventional Treatment of Gastric Variceal Hemorrhage: What Is Better? Moon Young Kim Gut and Liver.2018; 12(6): 611. CrossRef
Endoscopic Therapy for Variceal Bleeding: from Patient Preparation to Available Techniques and Rescue Therapies Philippe Sultanik, Dominique Thabut Current Hepatology Reports.2017; 16(4): 398. CrossRef
Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Clin Mol Hepatol 2016;22(3):382-389. Published online September 25, 2016
Background/Aims Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response.
Methods This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log10 IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal.
Results After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076–4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log10 IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log10 IU/mL (n=11) and >3 log10 IU/mL (n=28), respectively.
Conclusions The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log10 IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration.
Citations
Citations to this article as recorded by
Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries Ben Kang, Dae Yong Yi, Byung-Ho Choe Frontiers in Pediatrics.2022;[Epub] CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Drug Discovery Study Aimed at a Functional Cure for HBV Takehisa Watanabe, Sanae Hayashi, Yasuhito Tanaka Viruses.2022; 14(7): 1393. CrossRef
Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile Sheng-Jie Shiue, Chao-Ling Cheng, Han-Shiang Shiue, Chun-Nan Chen, Sheng-Wei Cheng, Li-Wei Wu, Ganbolor Jargalsaikhan, Tze-Sian Chan, Hsin-Yi Lin, Ming-Shun Wu Nutrients.2022; 14(14): 2790. CrossRef
Long‐term clinical outcome of HBeAg‐negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie‐Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis Liver International.2021; 41(1): 48. CrossRef
Advances in treatment and prevention of hepatitis B Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson Gut.2021; : gutjnl-2020-323979. CrossRef
Advances in treatment and prevention of hepatitis B Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B Florian van Bömmel, Thomas Berg Hepatology Communications.2021; 5(10): 1632. CrossRef
Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B Do Seon Song, Jeong Won Jang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon Clinical Infectious Diseases.2021; 73(4): e892. CrossRef
Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B Margarita Papatheodoridi, George Papatheodoridis Cells.2020; 9(2): 493. CrossRef
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson Viruses.2020; 12(9): 934. CrossRef
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef
Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao BMC Infectious Diseases.2020;[Epub] CrossRef
Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg‐negative chronic hepatitis B Hariklia Kranidioti, Spilios Manolakopoulos, George Kontos, Michael S. Breen, Anastasia Kourikou, Melanie Deutsch, Maria Ester Quesada‐Del‐Bosque, Rocio T. Martinez‐Nunez, Mohammed M. Naiyer, Christopher H. Woelk, Tilman Sanchez‐Elsner, Emilia Hadziyannis Journal of Viral Hepatitis.2019; 26(6): 697. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
New Biomarkers of Chronic Hepatitis B Lung-Yi Mak, Wai-Kay Seto, James Fung, Man-Fung Yuen Gut and Liver.2019; 13(6): 589. CrossRef
Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B Florian van Bömmel, Thomas Berg Liver International.2018; 38(S1): 90. CrossRef
An expert consensus for the management of chronic hepatitis B in Asian Americans M. J. Tong, C. Q. Pan, S.‐H. B. Han, D. S.‐K. Lu, S. Raman, K.‐Q. Hu, J. K. Lim, H. W. Hann, A. D. Min Alimentary Pharmacology & Therapeutics.2018; 47(8): 1181. CrossRef
Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease characterized by hepatocellular inflammation, necrosis, and fibrosis, which can progress to cirrhosis and fulminant hepatic failure. The standard treatment for AIH includes corticosteroids alone or in combination with azathioprine. Although most patients achieve remission using the standard regimen, some patients do not respond due to either drug intolerance or refractory disease; in such cases alternative immunosuppressive agents should be explored. The second-line therapies are cyclophilin inhibitors such as cyclosporine A or tacrolimus, and nowadays mycophenolate mofetil (MMF) is widely used if azathioprine-based therapies are not tolerated. Although these are recommended as an alternative to the first-line regimen, there is insufficient evidence for the efficacy of second-line therapies, with the evidence based mainly on expert opinion. Therefore, we report an AIH patient receiving the standard regimen in whom remission did not occur due to side effects to azathioprine, but was successfully treated with MMF in combination with corticosteroids as an alternative to the standard regimen.
Citations
Citations to this article as recorded by
Cytopenias in Autoimmune Liver Diseases—A Review Mohammed Abdulrasak, Ali M. Someili, Mostafa Mohrag Journal of Clinical Medicine.2025; 14(5): 1732. CrossRef
Inflammatory bowel disease and risk of autoimmune hepatitis: A univariable and multivariable Mendelian randomization study Gang Chi, Jinhong Pei, Xueqing Li, Alessandro Granito PLOS ONE.2024; 19(6): e0305220. CrossRef
Mycophenolate mofetil as a treatment for presumed idiopathic chronic hepatitis in dogs: Six cases (2010–2022) Michelle K. Beehler, Shawn A. Kearns, Zachary J. Crouse Veterinary Medicine and Science.2023; 9(6): 2527. CrossRef
Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy Vetriselvan Subramaniyan, Srikumar Chakravarthi, Ravindran Jegasothy, Wu Yuan Seng, Neeraj Kumar Fuloria, Shivkanya Fuloria, Iswar Hazarika, Anju Das Toxicology Reports.2021; 8: 376. CrossRef
Human Cytomegalovirus Upregulates Expression of HCLS1 Resulting in Increased Cell Motility and Transendothelial Migration during Latency Yusuf Aslam, James Williamson, Veronika Romashova, Elizabeth Elder, Benjamin Krishna, Mark Wills, Paul Lehner, John Sinclair, Emma Poole iScience.2019; 20: 60. CrossRef
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy Stuart K. Roberts, Ricky Lim, Simone Strasser, Amanda Nicoll, Alessia Gazzola, Joanne Mitchell, Way Siow, Tiffany Khoo, Zaki Hamarneh, Martin Weltman, Paul Gow, Natasha Janko, Edmund Tse, Gauri Mishra, En-Hsiang Cheng, Miriam Levy, Wendy Cheng, Siddharth Clinical Gastroenterology and Hepatology.2018; 16(2): 268. CrossRef
Alternative treatment regimens in autoimmune hepatitis: how justified is their choice? M. V. Matsievich, A. O. Bueverov, M. Yu. Petrachenkova Almanac of Clinical Medicine.2018; 46(5): 504. CrossRef
Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta‑analysis Feng‑Bin Lu, En‑De Hu Hu, Lan‑Man Xu, Yi‑Bing Hu, Lu Chen, Jin‑Lu Wu, Hui Li, Da‑Zhi Chen, Yong‑Ping Chen Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Diagnosis and Treatment of Autoimmune Liver Diseases in a Tertiary Referral Center in Cuba Marlen Ivón Castellanos Fernández, Deyanira la Rosa Hernández, Diego Enrique Cabrera Eugenio, Wilson Palanca, Zaily Dorta Guridi, Licet González Fabián Current Therapeutic Research.2017; 85: 8. CrossRef
Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments Benedetta Terziroli Beretta-Piccoli, Giorgina Mieli-Vergani, Diego Vergani World Journal of Gastroenterology.2017; 23(33): 6030. CrossRef
First
Prev
